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Drugs designed to act against individual molecular targets cannot usually combat multigenic 
diseases such as cancers in which alternative or compensatory pathways are often activated. Thus 
selection of proper multi-target combinations and prediction of new molecules against these 
selected multiple targets are highly useful for discovering drugs with improved therapeutic 
efficacies by collective regulations of primary therapeutic targets, compensatory signaling and 
drug resistance mechanisms.  
Cross-talk between pathways plays important regulatory roles in biological processes, disease 
processes, and therapeutic responses. Knowledge of these cross-talks is highly useful for 
facilitating systems level analysis of diseases, biological processes and the mechanisms of multi-
targeting drugs and drug combinations. However, to our best knowledge, currently no such 
database exists providing this kind of information. In this work, a Pathway Cross-talk Database 
(PCD) is developed providing information about experimentally discovered cross-talks between 
pathways and their relevance to diseases and biological processes thus facilitating multi-target 
selection. Based on some entries stored in PCD, four combinations of anticancer kinase targets, 
EGFR-VEGFR, EGFR-Src, EGFR-PDGFR and EGFR-FGFR were selected as illustration and 
for further study. 
In silico methods have been extensively explored for the discovery of multi-target drugs. Apart 
from drug lead optimization, predictive quantitative structure-activity relationship (QSAR) 
models with well-defined applicability domains (ADs) have shown promising capability in virtual 
screening (VS) large chemical databases for novel drug hits. Despite the good hit rates and 
activity assessment these QSAR models can achieve, however, these models cannot find highly 
novel actives outside similarity-based ADs. One possible reason is that ADs may only contain 
limited spectrum of active compounds. Another possible reason lies in the limited scaffold 
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hopping ability of the molecular descriptors, i.e. the chosen molecular descriptors may not be able 
to fully represent and identify molecules with similar properties yet different or novel scaffolds. 
Thus, an extended QSAR approach is needed aimed at finding highly novel inhibitors without 
compromising hit rates within similarity-based ADs. In this work, new MLR QSAR models are 
constructed via chemspace-wide activity regression and tested on DHFR, ACE and Cox2 
inhibitors, and further applied for searching for dual inhibitors of the four combinations of 
anticancer kinase targets, EGFR-VEGFR, EGFR-PDGFR, EGFR-FGFR and EGFR-Src. The 
results show our consensus SVR QSAR models yield equivalent predictive accuracy for newly 
discovered chemicals and improved hit-rates and enrichment factors in identifying inhibitors from 
large chemical databases. In particular, our method also shows some level of capability in the 
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CHAPTER 1 Introduction 
Drugs designed to act against individual molecular targets cannot usually combat multigenic 
diseases such as cancers in which alternative or compensatory pathways are often activated. Thus 
prediction of new molecules against selected multiple targets is highly useful for discovering 
multi-target drugs with improved therapeutic efficacies by collective regulations of primary 
therapeutic targets, compensatory signaling and drug resistance mechanisms. In this chapter, in 
Section 1.1, the rationale of adopting multi-targeted therapy for cancers over single-targeted 
treatments is summarized; in Section 1.2, recent progresses in exploration of in silico methods, 
especially Quantitative Structure-Activity Relationship (QSAR) methods (Section 1.3), for the 
discovery of multi-targeting drugs are described.  
1.1 From single- to multi-targeted cancer therapy 
Due to the complex mechanisms and signaling networks involved in oncogenesis, tumor invasion 
and proliferation, traditional monotherapies for cancers sometimes exhibit modest effects and 
some patients responding to certain therapeutic agents may eventually develop drug resistance. 
Multi-targeting agents represent the prospect for the future targeted cancer therapies. In this 
section, the rationale for the multi-targeted cancer therapy is described followed by the necessity 
of the involvement at the system level of the complex oncogenic pathways in multi-target 
selection. 
1.1.1 From single- to multi-targeted cancer therapy 
The main challenge of clinical cancer research is to find a therapeutic approach that specifically 
kills malignant cells with minimum possible adverse effects (AEs).
1
 However, until recently, the 
traditional treatment of cancers has majorly relied on cytotoxic chemotherapy.
1, 2
 Recent progress 
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in understanding the mechanisms involved in malignant transformation has offered targeted 
therapy,
3
 i.e. compounds inhibit specific tumor targets which significantly reduce undesired AEs 
on normal tissues, to achieve more effective and rational cancer treatment. Though a number of 
agents including monoclonal antibodies (mAbs) and small-molecule tyrosine kinase inhibitors 
(TKIs) have been approved for clinical use or in various stages of clinical development for 
monotherapy of cancers, the effectiveness of these agents seem to be moderate or be reduced with 
the development of drug resistance. This may be partially attributed to the existence of feedback 
loops or the activation of alterative oncogenic pathways.
1, 2, 4, 5
 For instance, targeted inhibition of 
epidermal growth factor receptor (EGFR) has been clinically validated in several solid tumors 
with a number of approved drugs.
2
 EGFR and vascular endothelial growth factor receptor 
(VEGFR) signaling pathways are independent yet interrelated with each other.
6
 EGF induces 
VEGF expression via activation of EGFR in human cancer cells,
6-8
 and conversely, VEGF 
expression may decrease via inhibition of EGFR signaling pathway.
8, 9
 However, it has been 
shown that the VEGF up-regulation independent of EGFR signaling may contribute to resistance 
to EGFR inhibition.
6, 10
 One proposed explanation involves cyclin D1 and Bcl-xL which have 
been found to be overexpressed in some tumor cells.
10
 Cyclin D1 associates with cyclin-
dependent kinase (CDK) 4 and facilitates cell cycle progression from G1 into the S phase. Bcl-xL 
functions as a repressor of cell death. Both cyclin D1 and Bcl-xL expression has been shown to 
be positively regulated by EGFR signaling and that down-regulation of these molecules by 
inhibiting EGFR is believed to be critical in their proapoptotic and growth-inhibitory effects.
11-13
 
Additionally, it has been shown that cyclin D1 overexpression may result in increased VEGF 
levels.
14
 High expression levels of Bcl-xL are also found to be independent of EGFR signaling,
10
 
which suggests a possible involvement of this antiapoptotic molecule in the resistant phenotype. 
With the approval by FDA of more multi-targeting drugs such as Sorafinib and Sunitinib, 
discovering molecules simultaneously interfering with multiple therapeutic targets or oncogenic 
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1.1.2 Multi-target molecular scaffolds 
Drugs typically interact with multiple proteins, and those interacting with selected combination of 
targets have found useful therapeutic applications.
15
 Multi-target drugs active against selected 
multiple targets of the same diseases have been increasingly explored
16, 17
 for achieving enhanced 
therapeutic efficacies and reduced drug resistance activities by simultaneously modulating a 
primary therapeutic target and drug response and resistance mechanisms.
18, 19
 Table 1.1 provides 




Table 1.1 Literature reported multi-target drugs, targeted diseases, potencies against individual targets and cell-lines, and multi-target mode of action 
 
Drug  Targeted Disease Multi-targets and 
potency against each 
individual target 
(IC50, Ki, EC50) 
Potency against specific cell 
line 
Multi-target mode of action 
ABT-263 Advanced small cell lung 
cancer;  Relapsed or 
refractory chronic 
lymphocytic leukemia;  
























Inhibiting Bcl-2 protein family members that 
regulate apoptosis and impact tumor formation, 












Inhibiting tyrosine kinase receptor ERBB family 
members that regulate proliferation and survival 
at different upstream points, and act as back-up 
alternative for each other 
AT9283   Adult solid tumors; NHL; 

















Inhibiting Aurora kinases that regulate prophase 
of mitosis (Aurora A) and the attachment of the 
mitotic spindle to the centromere (Aurora B) 
  
Axitinib Metastatic pancreatic 














Inhibiting cytokine and tyrosine kinases 
receptors that regulate cell proliferation at 























Inhibiting tyrosine kinases that regulate cell 
proliferation at different upstream points  
Batimastat Various cancers
21







 Inhibiting MMP proteases that regulate cell 
invasion and proliferation (MMP-1 and 7), 























Inhibiting tyrosine kinase receptor ERBB family 
members that regulate proliferation and survival 
at different upstream points 












Inhibiting tyrosine kinases that regulate cell 














Inhibiting monoamine transporter family 
members that perform complementary and 
compensatory actions on neural activities in 
synapse 
















Inhibiting tyrosine kinase receptor ERBB family 
members that regulate proliferation and survival 
at different upstream points  
Imatinib CML; GIST; Intestinal 
cancer; Myeloid leukemia; 













BV173: 240nM  
EM3: 100nM  




Inhibiting tyrosine kinases that regulate 
proliferation at different upstream points 
Lapatinib Refractory metastatic 
breast cancer; RCC; 













Inhibiting tyrosine kinase receptor ERBB family 
members that regulate proliferation and survival 
at different upstream points, and act as back-up 
alternative for each other 
Midostaurin Colon, breast, CLL, AML, 











Canine mastocytoma cell line 
C2: 157nM 
HMC-1.1 (lacking KIT 
D816V): 191nM 








Inhibiting tyrosine kinases that regulate cell 
























Inhibiting Aurora kinases that regulate prophase 
of mitosis (Aurora A) and the attachment of the 
mitotic spindle to the centromere (Aurora B)  
Motesanib GIST; Metastatic thyroid 













Inhibiting tyrosine kinase receptors that regulate 
proliferation (PDGFR), angiogenesis 
(VEGFR2), and kinase expression (KIT) 









Canine mastocytoma cell line 
C2: 55nM 
HMC-1.1 (lacking KIT 
D816V): 10nM 




Inhibiting tyrosine kinases that regulate tumor 














Inhibiting tyrosine kinase receptors that regulate 
cell proliferation (KIT) and angiogenesis 
(VEGFR2) 
P276-00 Multiple myeloma; Mantle 
cell lymphoma; Head & 













Inhibiting CDK family members that are 
involved in cell cycle regulation (CDK1 and 4) 
and transcription (CDK9) 
  
Pasireotide Neuroendocrine tumor;  













 Binding to multiple somatostatin receptor 
subtypes (i.e. 1, 2, 3, and 5) to mimic the action 
of natural somatostatin  
Pazopanib Advanced/metastatic renal 











 Inhibiting tyrosine kinase receptors that regulate 
cell proliferation and angiogenesis at different 


















Inhibiting Aurora kinases that regulate prophase 
of mitosis (Aurora A) and the attachment of the 
mitotic spindle to the centromere (Aurora B)  
PHA-739358 CML; MHRPC
21









Inhibiting Aurora kinases that regulate prophase 
of mitosis (Aurora A) and the attachment of the 
mitotic spindle to the centromere (Aurora B) 











 Inhibiting CDK family members that are 
involved in cell cycle regulation (CDK2), 
transcription (CDK9) and CDK activating and 
transcription (CDK7) 




syndrome; AML; Head & 























Inhibiting kinases that regulate angiogenesis 
(VEGFR2) and proliferation (BRAF), RET 
lysosomal degradation (RET), and Src-mediated 
alternative signalling (BRAF) 
  












 Inhibiting PKC family members that regulate the 
induction of transcription factors (PKC-alpha 
and beta) and sustainability of intracellular 
signals (PKC-theta) ,and in turn blocking T cell 
activation 
SU-6668 Advanced solid tumors
21















Inhibiting Aurora kinases that regulate prophase 
of mitosis (Aurora A) and the attachment of the 
mitotic spindle to the centromere (Aurora B), 
and tyrosine kinase receptors that regulate 
angiogenesis (FGFR, PDGFR and VEGFR2) 


















 Inhibiting tyrosine kinase receptors that regulate 
angiogenesis (PDGFR, VEGFR2), proliferation 
(FLT3), and kinase level (KIT) 
TAK165 Various cancers
28













Inhibiting tyrosine kinase receptor ERBB family 
members that regulate proliferation and survival 
at different upstream points  
TKI258 RCC
21









Inhibiting tyrosine kinase receptors that regulate 
survival and growth (FLT3), and angiogenesis 
and tumor progression (FGFR3) 














 Inhibiting Aurora kinases that regulate prophase 
of mitosis (Aurora A) and the attachment of the 
mitotic spindle to the centromere (Aurora B) 













Inhibiting tyrosine kinases that regulate tumor 
growth (c-MET) and angiogenesis (VEGFR2) 
  
ZK 304709 Advanced solid tumors
21











Inhibiting CDK family members that are 
involved in cell cycle regulation (CDK1, 2 and 
4), transcription (CDK9) and CDK activating 
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Some molecular scaffolds have been found in high percentages of multi-target agents against 
selected targets.  For instance, the six scaffolds in Figure 1.1 are reportedly contained in high 
percentages of the published dual inhibitors of tyrosine kinase pairs EGFR-PDGFR, PDGFR-Src, 
EGFR-Src, EGFR-FGFR, VEGFR-Lck, Src-Lck, and PDGFR-FGFR published before 2010.
87
 
The seven scaffolds in Figure 1.2 are in high percentages of the published dual inhibitors of 
serotonin reuptake paired with noradrenaline transporter, H3 receptor, 5-HT1a receptor, 5-HT1b 
receptor, 5-HT2c receptor and Neurokinin 1 (NK1) receptor respectively.
88
  Some scaffolds have 
been found to form multi-target activity scaffolds with their structural analogues having 
significantly different potencies against multiple targets.
89
 For instance, the two scaffolds in 
Figure 1.3 are in some inhibitors of carbonic anhydrase (CA) I, II and IX and some inhibitors of 
protein kinase B (PKB) Akt1 and Akt2, mitogen- and stress-activated protein kinase 1 (MSK1) 
and ribosomal S6 kinase 1 (RSK1) respectively, each with close analogues showing highly 
different potencies against different targets.
89
 In particular, analogues a and b of scaffold A, and 
analogues b and c of scaffold B show markedly different pIC50 values (activity cliff). These and 
other multi-target scaffolds appear to be the backbone of multi-target inhibitors of selected targets, 
and specific variations of side-chain groups of these scaffolds seem to be sufficient to 
significantly alter multi-target activities. This suggests that structural and physicochemical 
























































































Figure 1.1 Six scaffolds contained in high percentages of the dual inhibitors of tyrosine kinase pairs. 
These tyrosine kinase pairs include EGFR-PDGFR, PDGFR-Src, EGFR-Src, EGFR-FGFR, VEGFR-Lck, 
Src-Lck, PDGFR-FGFR, and PDGFR-Src published before 2010. The percentage value behind each target-
pair indicates the percentage of known dual inhibitors of the target-pair that contain this scaffold. 
















































Figure 1.2 Seven scaffolds reportedly contained in high percentages of the published dual inhibitors of 
serotonin reuptake paired with other targets. 
The listed dual inhibitors are those of serotonin reuptake paired with noradrenaline transporter, H3 receptor, 
5-HT1a receptor, 5-HT1b receptor, 5-HT2c receptor, Melanocortin 4 receptor and Neurokinin 1 receptor 
respectively. The percentage value behind each target-pair indicates the percentage of known dual 
inhibitors of the target-pair that contain this scaffold. 




























































































Figure 1.3 Two molecular scaffolds in some multi-target inhibitors of CAI, CAII and CAIX and some 
inhibitors of Akt1, Akt2, MSK1 and RSK1 respectively. 
Each of these two scaffolds are with representative multi-target analogues showing potencies in pIC50 
against respective target combinations. In particular, analogues a and b of scaffold A, and analogues b and 
c of scaffold B show markedly different pIC50 values (activity cliff). 
 
1.1.3 Proposed prospect of multi-target selection 
Modern drug discovery is primarily focused on the search or design of drug-like molecules, 
which selectively interact and modulate the activity of one or a few selected therapeutic targets.
16, 
90, 91
 One challenge in drug development is to choose and explore promising targets from a 
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growing number of potential targets.
92
 Target selection is of significant importance not only for 
achieving therapeutic efficacy but also for increasing drug development odds, given that few 
innovative targets have made it to the approved list each year (12 innovative targets in 1994–
2005
93
 and 10 new human targets in 2006–201094 for small molecule drugs).  
Traditionally, the selected drug target is a single gene or gene product based on genetic analysis 
and biological observations.
95
 Pathway analysis approaches have also been incorporated in the 
process of target selection
95, 96
 especially for cancers due to the reliance of these signaling 
pathways on the action of protein kinases whose dysregulation largely contributes to oncogenesis 
and tumor progress.
95
 However, drugs targeting specific single pathways exhibit limited efficacies, 
undesired AEs and resistance profiles often resulted from the multi-factorial mechanisms of 
cancers
95
 and the activation of alterative pathways
1, 2, 4, 5
 or pathway cross-talks.
97
  
One example has been described in Section 1.1.1 that the VEGF up-regulation independent of 
EGFR signaling may contribute to resistance to EGFR inhibition in treating non-small cell lung 
cancer (NSCLC).
6, 10
 Another instance can be illustrated by the cross-talk between insulin-like 
growth factor (IGF) signaling and integrin signaling pathways that affects the phenotype of breast 
cancer.
97
 IGFs protect breast cells from apoptosis and promote survival and IGF signaling has 
been proven to be a fit drug target for the treatment of breast cancer.
98, 99
 Integrin signaling plays 
important role in the development and progression of tumors in breast cancer.
100
 Moreover, the 
dependence of the IGF system on Integrin signaling pathway has also been demonstrated. For 
example, v3 integrin associates with IGF1R and alters IGF-1 stimulated signaling and cell 
migration.
101
 Another mechanism of the interaction between IGF and integrin signaling pathways 
may recruit focal adhesion kinase (FAK) and insulin receptor substrate (IRS) proteins as 
mediators.
97
 FAK is a primary mediator of integrin signaling.
97
 The activation of IRS-1 has been 
shown to be associated with IGF mediated proliferation, while IRS-2 is involved in cell 




 FAK has been reported to be activated by IGF1R
102
 and IRS proteins are substrates of 
FAK.
103
 Furthermore, IGF promotes the redistribution of FAK and IRS-2 to membrane terminals 
of breast cancer cells during cell migration.
97
 Therefore, the integrin occupancy is required for the 
maximal effect of IGF stimulated phenotypes and the IGF system can feed into the integrin 
system to mediate inside-out signaling.
97
 Thus, although modulating a single target has been 
proven to be beneficial, targeting multiple signaling pathways, especially cross-talking pathways 
e.g. IGF and integrin systems simultaneously to inhibit the advancement of IGF-responsive breast 
cancer, may prove more efficacious. 97  
Therefore, knowledge of pathway cross-talks promises to supplement and facilitate current target, 
especially multi-target, discovery and multi-target therapeutic strategies. Increasingly 
accumulated information on experimentally determined pathway cross-talks is readily available in 
published literature. However, to our best knowledge, no such database is available to 
comprehensively collect and provide such information in an organized pattern. To this end, in 
Chapter 3, a Pathway Cross-talk Database (PCD) is developed to fill in this blank thus 
facilitating the multi-target selection in drug discovery for achieving enhanced therapeutic 
efficacies and reduced drug resistance activities.  
1.2 In silico prediction of multi-target agents 
There have been increasing interests in discovering multi-target drugs
104
 by means of 
experimental and in silico methods.
20, 105
 In particular, a number of in silico methods have been 
used for predicting multiple targets of known drugs and newly designed molecules.
20
 These 
methods are broadly classified into fragment-based, structure-based and ligand-based methods. 
Fragment-based methods combine multiple structural frameworks of active molecules of 
individual target into a single molecule that binds to multiple targets.
106
 Structure-based methods, 
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such as molecular docking,
107-109
 target-site structural similarity
110
 and receptor-based 
pharmacophore searching,
111
 explore target site structural features to find binding molecules with 
structural and energetic complementarity. Ligand-based methods use such techniques as 
similarity searching,
112, 113
 drug side effect similarity,
114
 quantitative structure-activity 
relationships (QSAR),
115-121
 and machine learning methods
87, 88
 to select molecules with structural 
and physicochemical profiles matching those of the known active molecules. In this section, 
recent progresses are described in exploring these methods for predicting polypharmacology 
aimed at multi-target drug discovery. 
1.2.1 Fragment-based methods for prediction of multi-target agents 
Fragment-based approaches have also been explored for designing multi-target agents.
106
 One 
method, framework combination, incorporates essential binding features into a single lead 
molecule by linking, fusing or merging the frameworks of two selective molecules.
106
 However, 
this method may in some cases generate large, complex and less drug-like molecules.
106
 Drug-
likeness can be retained if the degree of framework overlap is maximized and the size of the 
selective ligands minimized. Another method, screening-based method, searches chemical 
(fragment) libraries to find multi-target fragment hits possibly with weak activities, followed by 
optimization of the fragment into more potent multi-target active agents.
106
 Optimizing fragments 
with weak multiple activities into potent multi-target drug-like agents can be more easily 
achieved for targets sharing a conserved binding site.
122
 As binding sites become more dissimilar, 
it remains a challenge to design agents with potent multi-target activities, in vivo efficacy and 
safety profiles. One solution is to explore synergistic targets, such that multi-target agents with 
modest activity against one or more of these synergetic targets may still produce similar or better 
in vivo effects compared to higher-affinity target-selective compounds.
123
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1.2.2 Structure-based methods for prediction of multi-target agents 
Two structure-based methods, molecular docking and receptor-based pharmacophore searching, 
have been extensively used for facilitating the identification of multi-target molecules. In 
particular, molecular docking method does not require knowledge about known active 
compounds and their structural features or frameworks, but in some cases may have limited 
capability in account of target structural flexibility and specific chemical features of drug binding. 
To improve virtual screening performance, molecular dynamics enhanced molecular docking 
method has been used in virtual screening against the individual targets in HIV and its associated 
opportunistic pathogens to find multi-target agents such as KNI-764 that inhibits both HIV-1 
protease and malarial plasmepsin II enzyme.
124
 Molecular docking and pharmacophore matching 
methods have been used for identifying dual-inhibitors of two anti-inflammatory targets, PLA2 
and LTA4H-h, in the arachidonic acid metabolic network.
125
 Combined receptor-based 
pharmacophore searching and molecular docking have been used for identifying multi-target 
Chinese herbal ingredients against four anti-inflammatory targets cyclooxygenases 1 & 2, p38 
MAP kinase, c-Jun terminal-NH2 kinase and type 4 cAMP-specific phosphodiesterase.
126
 
1.2.3 Ligand-based methods for prediction of multi-target agents 
Some ligand-based methods have also been used for identifying multi-target active compounds. 
In particular, a number of multi-target QSAR models have been developed for identifying multi-
target kinase inhibitors,
115












species have been developed by incorporating  multi-target or species variations of binding-site 
features into the multi-target dependent molecular descriptors or species-dependent molecular 
descriptors, and stochastic Markov drug-binding process models. These multi-target QSAR 
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models have been reported to achieve high retrieval rates of 72%~85% and moderately low false-
hit rates of 15%~28%.
119-121
  Development of multi-target QSAR models may be limited by the 
inadequate number of drug data for some of the targets or species. Moreover, the molecular size 
of the testing drugs needs to be in a certain range for accurate computation of multi-target 
dependent or species-dependent molecular descriptors, which in some cases may also affect one’s 
capability for developing multi-target QSAR models.
121
 
Another ligand-based method, machine learning method, has also been explored as virtual 
screening tools for multi-target drug discovery. Combinatorial SVM models for searching dual 
inhibitors of 11 kinase pairs have been developed, for which in silico tests have shown reasonably 
good dual kinase inhibitor yields (12.2%-57.3%), hit rates (0.22%~4.3%), and selectivity against 
individual kinase inhibitors (individual kinase inhibitor false selection rates 3.7%-48.1% for the 
same kinase pair and 0.98%-4.77% for other kinases) in screening 13.56 million compounds.
88
 
Some of the SVM  selected virtual hits that passed drug-like filter and molecular docking have 
been tested in bioassays, which have found that 3 of the 19 selected dual Abl and PI3K inhibitor 
hits,
127
 1 of the 21 selected dual VEGFR2 and Src inhibitor hits
128
 and 1 selected dual EGFR and 
VEGFR inhibitor hit
129
 are active. Combinatorial SVM has also been applied for predicting dual 
target serotonin reuptake inhibitors of 7 target pairs, and in silico tests have shown similar level 
of dual target inhibitor yields (22.0%~83.3%), hit rates (0.12%~12.6%), and selectivity against 
individual target inhibitors (individual target inhibitor false selection rates 2.2%-29.8% for the 
same target pair and 0.58%-7.1% for other similar targets) in screening 17 million compounds.
88
  
1.3 Predictive QSAR models as virtual screening tools 
Apart from drug lead optimization, QSAR models have been developed for searching drug leads, 
particularly novel ones, from large chemical libraries.
130-137
 These models achieve good hit rates 
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and activity assessment by pharmacophoric-shim adjusted molecular docking (PSA-Docking),
130-
132
 Bayesian-based target-family activity profiling (BTFAP),
133
 and machine learning regression  
(MLR) of known actives
134-137
 within applicability domains (ADs) defined by binding-mode 
constraints,
130
 Baysian active-inactive boundaries,
133, 138
 and range-based and distance-based 
similarity to the known actives.
139, 140
 In particular, MLR requires no knowledge of target 3D 
structure or target-family activity profiles.
141
 A few examples of recent MLR QSAR models VS 
applications are highlighted below.  
1.3.1 Discovery of novel D1 dopaminergic antagonists 
Dopamine receptors are implicated in many neurological processes, including motivation, 
pleasure, cognition, memory, learning, and fine motor control, as well as modulation of 
neuroendocrine signaling.
142
 Abnormal dopamine receptor signaling and dopaminergic nerve 
function is implicated in several neuropsychiatric disorders
142
 and makes dopamine receptors 
common neurologic drug targets. Dopamine D1 receptor antagonists inhibited cell depolarization 
by preventing the activation of D1 receptor. However, the number of current drugs targeting D1 
receptor is limited with 3 approved for marketing and another 2 under preclinical studies.
21
 QSAR 
models were developed by comparative molecular field analysis (CoMFA), simulated annealing-
partial least squares (SA-PLS), k-nearest neighbor (kNN), and support vector machines (SVM) 
approaches for 48 antagonists of the dopamine D1 receptor and applied to the VS of chemical 
databases to discover novel potential antagonists.
135
 Validated QSAR models were used to mine 3 
publicly available chemical databases:  the National Cancer Institute (NCI) database, the 
Maybridge database and the ChemDiv database and resulted in 54 consensus hits. 5 of these 54 
virtual hits were previously reported as dopamine D1 ligands, but were not included in the 
original dataset. A small fraction of the purported D1 ligands did not contain a catechol ring 
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1.3.2 Discovery of novel histone deacetylase (HDAC) inhibitors 
Histone deacetylases (HDACs) modulate chromatin structure and transcription.
143
 HDAC 
inhibitors have long been used in psychiatry and neurology as mood stabilizers and anti-epileptics. 
In more recent times, HDACs have become emerging target for the cancer treatment. In another 
work of Tropsha’s group, QSAR models were generated by Tang et al. by kNN and SVM 
approaches for 59 diverse class I HDAC inhibitors.
137
 Validated consensus QSAR models were 
then used to virtual screen 3 million compounds from 4 chemical databases: National Cancer 
Institute (NCI) database, Maybridge database, ChemDiv database and ZINC database. The 
searches resulted in 48 consensus hits, including 2 reported HDAC inhibitors that were not 
included in the original data set. 4 virtual hits with novel structural features were purchased and 
tested using the same biological assay that was employed to assess the inhibition activity of the 
training set compounds. 3 of these 4 compounds were confirmed active with the best inhibitory 
activity (IC50) of 1 M.
137
 
1.3.3 Discovery of novel Geranylgeranyltransferase type I (GGTase-I) inhibitors 
Geranylgeranyltransferase posttranslationally modify proteins by adding an isoprenoid lipid 
called a prenyl group to the carboxyl terminus of the target protein. This process, called 
prenylation, causes prenylated proteins to become membrane-associated due to the hydophobic 
nature of the prenyl group. Most prenylated proteins are involved in cellular signaling, wherein 
membrane association is critical for function.
144
 GGTase-I inhibitors have therapeutic potential to 
treat inflammation, multiple sclerosis, atherosclerosis, and many other diseases.
145, 146
 In a recent 
study, Peterson et al. constructed kNN, GA-PLS and automated lazy learning QSAR models for 
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48 diverse GGTase-I inhibitors and used the validated models to VS 9.5 million commercially 
available chemicals.
136
 This yielded 47 consensus virtual hits, 7 of which were with novel 




Despite the good hit rates and activity assessment these models can achieve, however, these 
models cannot find highly novel actives outside similarity-based ADs. One possible reason is that 
ADs may only contain limited spectrum of active compounds. Another possible reason lies in the 
limited scaffold hopping ability of the molecular descriptors, i.e. the chosen molecular descriptors 
may not be able to fully represent and identify molecules with similar properties yet different or 
novel scaffolds. Thus, an extended QSAR approach is needed aimed at finding highly novel 
inhibitors without compromising hit rates within similarity-based ADs. In Chapter 4, new MLR 
QSAR models are constructed via chemspace-wide activity regression and tested on 
dihydrofolate reductase (DHFR), angiotensin converting enzyme (ACE) and cyclooxygenase-2 
(Cox2) inhibitors, and further applied for VS of EGFR-VEGFR, EGFR-PDGFR, EGFR-FGFR 
and EGFR-Src dual inhibitors in Chapter 5.  
1.4 Objectives and outline of this work 
As described in previous sections, knowledge of pathway cross-talks is of significant importance 
to supplement and facilitate current multi-target discovery and therapeutic strategies. Increasingly 
accumulated information on experimentally determined pathway cross-talks is readily available in 
published literature. However, no such database is available to comprehensively collect and 
provide such information in an organized pattern. On the other hand, despite that the current 
QSAR models can achieve satisfactory hit rates and activity assessment, however, the ability of 
these models for yielding highly novel inhibitors are still limited, especially for those are outside 
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similarity-based ADs. Therefore, in this work, we majorly aim to achieve the following two 
objectives: 
1) To develop a database comprehensively collect and provide experimentally determined 
pathway cross-talks to facilitate the multi-target selection in drug discovery for achieving 
enhanced therapeutic efficacies and reduced drug resistance activities.  
2) To develop an extended QSAR method via chemspace-wide activity regression that is 
capable of finding highly novel single- and multi-target inhibitors while without 
compromising hit rates within similarity-based ADs.  
In summary, this dissertation is organized in the following manner: 
In Chapter 1, the rationale of the multi-targeted cancer therapies is described coupled with the 
importance of employing knowledge of pathway cross-talks facilitating this process. A list of in 
silico methods, e.g. QSAR method, for the prediction of the multi-target agents is reviewed. In 
particular, the performance of validated QSAR models screening large chemical databases for 
virtual hits is also summarized.  
In Chapter 2, details of the methods used in this work are described. In particular, the strategy 
for developing a Pathway Cross-talk Database is presented in every detail together with the data 
preparation process, the molecular descriptors calculation, mathematical models of various 
statistical learning methods used for the high throughput QSAR model development in this work, 
and the model evaluation methods. 
In Chapter 3, a Pathway Cross-talk Database (PCD) is developed providing information about 
experimentally discovered cross-talks between pathways and their relevance to diseases and 
biological processes, mechanism of multi-target drugs and drug combinations. In this chapter, the 
data source, structure and access of PCD are introduced in details. The usefulness of PCD in 
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facilitating system level studies of diseases and mechanism of drug combinations and, especially, 
multi-targeting drugs is also demonstrated.  
In Chapter 4, a high throughput SVR QSAR approach is developed via chemspace-wide activity 
regression aimed at finding highly novel inhibitors without compromising hit rates within 
similarity-based applicability domains. This SVR QSAR approach is tested on DHFR, ACE and 
Cox2 inhibitors for predicting the activities of “new” inhibitors reported after the year of 2010 
and for identifying inhibitors from large chemical databases.   
4 combinations of 5 anticancer kinases, EGFR-VEGFR, EGFR-PDGFR, EGFR-FGFR and 
EGFR-Src, are selected in Chapter 3 as some of the promising anti-NSCLC drug targets by the 
systems level analysis of the cross-talks between signalings initiated by these kinases. Thus in 
Chapter 5, the SVR QSAR approach is applied as the VS tool for searching dual inhibitors of 
these kinase combinations.  
Finally, in the last chapter, Chapter 6, major findings and contributions of current work for the 
development and application of PCD and the high throughput SVR QSAR approach are discussed. 
Limitations and suggestions for future studies are also rationalized in this chapter.   
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CHAPTER 2 Materials and Methods 
2.1 Development of systems biological network database 
Database development has shown a broad spectrum of application in scientific research. 
Specifically, system biological databases aiming at providing comprehensive and systematic 
information for bioinformatics and pharmaceutics-related research have been widely utilized in 
the study of mechanism of diseases, identification of rational drug targets and discovery of novel 
drug hits, multi-targeting drugs and drug combinations and etc. Despite their various applications 
in biological and pharmaceutical research, the general strategy adopted for constructing these 
databases is similar. In this section, the basic strategy for developing knowledge-based systems 
biological network databases is demonstrated, which will then be extended to construct Pathway 
Cross-talk Database (PCD). More details on this database will be introduced later in Chapter 3.  
Generally, the development of a database is a process including rational architecture design, 
information accumulation, optimal data storage and user-friendly data access and representation. 
2.1.1 Rational architecture design 
Before constructing any bioinformatics databases, a rational design of architecture will help us to 
define the scope of the database, focus on certain pharmaceutical problem, and pave the way for 
the information collection. At this stage, the objective and content of the database should be 
seriously considered. As summarized in Chapter 1, cross-talk between pathways plays important 
regulatory roles in biological processes, disease processes, and therapeutic responses. Knowledge 
of these cross-talks is highly useful for facilitating systems level analysis of diseases, biological 
processes and the mechanisms of multi-targeting drugs and drug combinations. However, 
currently there is no such database. Developed in the year of 2008, the Pathway Cross-talk 
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Database (PCD) was designed to provide information about experimentally discovered cross-talks 
between pathways and their relevance to diseases and biological processes, mechanism of multi-
target drugs and drug combinations. 
2.1.2 Information mining for system biological databases 
Generally, a knowledge-based bioinformatics database is designed to provide sufficient domain 
knowledge on a specific subject in biology and pharmacology. Take PCD as an example, PCD 
was designed to provide information about experimentally discovered cross-talks between 
pathways thus facilitating the understanding of mechanisms of diseases and cellular processes, 
and discovery of multi-target drugs and drug combinations. For a single entry in PCD, knowledge 
is incorporated at various levels including genes, ligands, proteins, distinct single pathways and 
cross-talk networks.  
The information planned to be integrated can be selected from a comprehensive search of 
literature and research publications. In light of the diversity of information types, the methods 
used for data collection vary, but one thing in common is to seek data from reliable resources. At 
present, no ready index or library is available and almost all the relevant information is scattered 
in the huge amount of biological and medical literature. Therefore, literature information 
extraction is considered to be one of the most feasible ways for information mining. It is 
generally agreed that literature are typically unstructured data source, and the terms used in 
different sources, which may be in synonymous name, various abbreviations, or totally different 
expression, are difficult to be recognized by automatic language processing. An automated 
literature information extraction system solely relying on computational recognition, thus, cannot 
be invented to gather information from literature both efficiently and accurately. 
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In this work, automatic text mining methods with manual reading process was combined. 
Automated text retrieval programs developed in Perl were used to screen the literature that 
contained the key words in the local Medline abstract packages.
147
 Then, the useful subject 
information was picked up manually from these matched Medline abstract. If necessary, the full 
literature was referred to facilitate information searching. Meanwhile, in many cases, the relevant 
information about the same subject could also be found in the same literature. Therefore, in the 
first step, not only subjects but also relevant information could be obtained and recorded. In the 
second step, detailed biological information of subjects was automatically selected from some 
general or specific biological databases, such as SwissProt, KEGG and etc., by text mining 
program. Likewise, other information derived from the subjects was also extracted from the 
corresponding databases in the same way. On collecting sufficient high quality information, data 
storage, organization and management and design of database structure is the next step, which 
will be described in the next section.  
2.1.3 Data organization and database structure construction 
A good database system enables users to create, store, organize, and manipulate data effectively 
and efficiently. By integrating databases and web sites, users and clients can open up possibilities 
for data access and dynamic web content. An integrated information system of a database should 
be constructed according to some standardization strategies as follows: 
1) Establishment of standardized data format and appropriate data model 
2) Database structure construction 
3) Development of Database Management System (DBMS) 
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Since the original data information collected in previous section is independent, the first major 
activity of a database construction process includes creation of digital files from these 
information fragments and construction of an appropriate data model. 
2.1.3.1 The database model 
Database model is an integrated collection of concepts for describing data, relationships between 
data, and constraint on data. In other words, a database model is a specific description on how a 
database is structured and used. The basic ways of constructing databases include:  
1) The flat file model 
2) The hierarchical model 
3) The network model 
4) The relational model 
5) The object-oriented model 
The flat-file model is the simplest data model, which is essentially a plain table of data.
148
 Each 
item in the flat file, called a record, corresponds to a single, complete data entry. A record is made 
up by data elements, which is the basic building block of all data models, not just flat files. The 
flat-file data model is relatively simple to use; however, it is insufficient for large databases. 
The hierarchical data model organizes data in a tree-like structure (Figure 2.1).
149
 It has been 
used in many well-known database management systems. The structure allows representing 
information using parent/child relationships: each parent can have many children, but each child 
has only one parent (also known as a 1-to-many relationship).
149
 All attributes of a specific record 
are listed under an entity type. This database structure was one of the first used because it lends 
itself very well to linear type storage mediums, such as the data tapes that were used when 
database were first created. However, this model has many issues that hold it back now that we 
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require more sophisticated relationships.  It requires data to be repetitively stored in many 





Figure 2.1 The hierarchical data model 
 
In most cases, the relationships of data would be arbitrarily complex (Figure 2.2). In this model, 
some data are more naturally modeled with multiple parents per child. So, the network model 
permits the modeling of many-to-many relationships in data. This model, thus, can handle varied 
and complex information while remaining reasonably efficient. Even so, the biggest problem with 
the network data model is that databases can get excessively complicated. 
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Figure 2.2 The network data model 
 
 
Figure 2.3 The rational data model 
 
The relational model was formally introduced in 1970
151
 and has been extensively used in 
biological database development (Figure 2.3). The model is a much more versatile form of 
database. On the basis of this kind of data model, a novel system named relational database 
management system
152
 is established. A relational database allows the definition of data structures, 
storage and retrieval operations and integrity constraints. In such a database the data and relations 
between them are organized in tables. 
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A relational database consists of multiple tables of data, related to one another by columns that 
are common among them.
151
 Each table is a collection of records and each record in a table 
contains the same fields.
151
 Therefore, if the database is relational, we can have different tables 
for different information. And the common columns, such as entry ID, can be used to relate the 
different tables. Relational database is the predominant form of database in use today, especially 
in biological research field. 
The object-oriented database (OODB) paradigm
153-155
 is “the combination of object-oriented 
programming language (OOPL) systems and persistent systems”.156 “The power of the OODB 
comes from the seamless treatment of both persistent data, as found in databases, and transient 
data, as found in executing programs”.156 The database functionality is added to object 
programming languages in object database management systems, which extend the semantics of 
the C++, Smalltalk and Java object programming languages to provide full-featured database 
programming capability. The combination of the application and database development with a 
data model and language environment is a major advantage of the object-oriented model. As a 
result, applications require less code, use more natural data modeling, and code bases are easier to 
maintain. 
2.1.3.2 Construction of relational database structure 
The relational model has been used in our system biological network databases. It represents 
relevant data in the form of two-dimension tables. Each table represents relevant data collected. 
The two-dimensional tables (Figure 2.4) for the relational database include the entry ID list table, 
the main information table, which contains a record for the basic information of each entry, data 
type table, which demonstrates the meaning represented by different number, and reference 
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Figure 2.4 Logical view of databases 
 
Figure 2.4 is a general logical view of databases. It shows the organization of relevant data into 
relational tables. In these tables, certain fields may be designated as keys, by which the separated 
tables can be linked together to facilitate searching specific values of that field. Commonly, in 
relational table, the key can be divided into two types. One is primary key, which uniquely 
identifies each record in the table. Here it is a normal attribute that is guaranteed to be unique, 
such as entry ID in entry ID list table with no more than one record per entry. The other is foreign 
key, which is a field in a relational table that matches the primary key column of another table. 
The foreign key can be used to cross-reference tables. For example, in tables of our databases, 
there are two foreign keys: Data type ID and Reference ID. According to Figure 2.4, a 
connection between a pair of tables is established using a foreign key. The two foreign keys make 
three tables relevant. Generally, there are three basic types of relationships of related table: one-
to-one, one-to-many, and many-to-many. In our case, these databases belong to one-to-many 
relationships. 
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2.1.3.3 Development of Database Management System (DBMS) 
By using relational database construction software (e.g. Oracle, Microsoft SQL Server) or even 
the personal database systems (e.g. MS Access, Fox), data stored in a database can be effectively 
organized and managed. This kind of data storage and retrieval system is called Database 
Management System (DBMS). In this work, MS Access DBMSs were used to define, create, 
maintain and provide controlled access to our databases and repository. All entry data from 
structured tables described in previous section are brought together for user display and output 
using SQL queries. 
2.2 High throughput QSAR models for virtual screening of drug hits 
The process of developing a QSAR model starts with the collection of high quality activity data 
and the elimination of low quality ones that are likely to affect the accuracy of the model. The 
next step is the selection of representative compounds into a training set and validation sets to 
calibrate and evaluate the QSAR model respectively. Molecular descriptors are then computed for 
representing the physicochemical and structural properties of the compounds studied, and those 
that are redundant or contain little information are removed prior to the modeling process. 
Regression methods, in this study the Support Vector Regression (SVR) method, are then used to 
develop a model that relates the investigated activities of the compounds to their physicochemical 
and structural properties. 
2.2.1 Data preparation 
Generally speaking, the performance of QSAR models largely depends on the chemical data 
quality and diversity of chemical data coverage in the training sets, thus the employment of a 
systematical chemical record preparation protocol would be helpful in the pre-processing of the 




 This data preparation process includes high quality data collection, chemical 
structure (and when possible, associated biological data) curation, and adequate representation of 
active and inactive chemicals in training datasets. 
2.2.1.1 Data source 
Data accessibility is critical for the success of a drug discovery and development. Huge amounts 
of small molecules and their related information have been accumulated in scientific literature 
and databases. Some important small molecule databases are given in Table 2.1.  
In this work, datasets including chemical structures and interested biological activities e.g. IC50, 
EC50, Ki and etc. are mainly collected from the journals (Bioorganic & Medicinal Chemistry 
Letters, Bioorganic & Medicinal Chemistry, European Journal of Medicinal Chemistry, European 









, etc.).   
Table 2.1 Some small molecule databases available online 
 
Database Name URL 
BindingDB http://www.bindingdb.org/bind/index.jsp 
MDDR http://accelrys.com/products/databases/bioactivity/mddr.html   
PubChem  http://pubchem.ncbi.nlm.nih.gov/ 
ZINC  http://zinc.docking.org/  
ChEMBL http://www.ebi.ac.uk/chembl/  
DrugBank  http://www.drugbank.ca/  
eMolecules  http://www.emolecules.com/  
WOMBAT http://www.sunsetmolecular.com 
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2.2.1.2 Chemical data curation 
Any error in the structure may cause inability to calculate molecular descriptors for erroneous 
chemical records or resulted in erroneous molecular descriptors. QSAR models developed with 
these incomplete or inaccurate molecular descriptors may be applicable to only a fraction of 
available data or even make the models inaccurate.
157
 The simple, but important, steps for 
cleaning chemical records in a dataset include the removal of a fraction of the chemical records 
that cannot be appropriately handled by conventional cheminformatics techniques, e.g. inorganic 
and organometallic compounds, counterions, salts and mixtures; structure validation; ring 
aromatization;  normalization of specific chemotypes; curation of tautomeric forms; and the 
deletion of duplicates and outliers
157
. In this study, the 2D structure of each of the compounds 
was generated by using ChemDraw or downloaded from other database like PubChem, 
BindingDB,
159
 ChEMBL and etc. and was subsequently converted into 3D structure by using 
CORINA.
162
 All the generated geometries had been fully optimized without symmetry 
restrictions. The 3D structure of each compound was manually inspected to ensure that the 
chirality of each chiral agent was properly generated. All salts and elements, such as sodium or 
calcium, were removed prior to descriptor calculation.  
The development of reliable pharmacological property QSAR models also depends on the 
availability of high quality pharmacological property descriptor data with low experimental 
errors.
163
 Ideally, these pharmacological properties descriptors should be measured by a single 
protocol so that different compounds can be reliably compared with each other. However, some 
pharmacological property descriptors have been measured only for a limited number of 
compounds and these data are rarely determined by the same protocol. Thus data selection has 
been primarily based on comparison of data of compounds commonly studied by different 
protocols, and incorporation of additional experimental information. For this work, several 
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methods are adopted to ensure that inter-laboratory variations in experimental protocols do not 
significantly affect the quality of the training sets. The sources for the pharmacological property 
descriptor data for each compound were investigated to remove the chemical records with 
extreme property descriptors and to ensure that there were no wide variations in experimental 
protocols from those of the majority of the compounds in the training set. Compounds that were 
investigated in more than one source are used to estimate the quality of each source.  
2.2.1.3 Generation of putative inactive compounds 
Active datasets could be generated from available active datasets of sufficiently high number of 
known actives and varying degrees of structural diversity. On the other hand, putative inactive 
datasets could be generated by extracting representative compounds from all compound families 
that contain no known active compound.
164
 Compound families can be generated by clustering 
distinct compounds of chemical databases into groups of similar structural and physicochemical 
properties.  
Apart from the use of known inactive compounds and active compounds of other biological target 
classes as putative inactive compounds,
165-172
 a new approach extensively used for generating 
inactive proteins in SVM classification of various functional classes of proteins
173-175
 has recently 
been applied for generating putative inactive compounds.
176
 An advantage of this approach is its 
independence on the knowledge of known inactive compounds and active compounds of other 
biological target classes, which enables more expanded coverage of the “inactive” chemical space 
in cases of limited knowledge of inactive compounds and compounds of other biological classes. 
In applying this approach to proteins, all known proteins are clustered into ~8,933 protein domain 
families based on the clustering of their amino acid sequences,
177
 and a set of putative inactive 
proteins can be tentatively extracted from a few representative proteins in those families without a 
single known active protein. By using this method, a reasonably good SVM classification model 
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In a similar manner, known compounds can be grouped into compound families by clustering 
them in the chemical space (PubChem database) defined by their molecular descriptors.
179, 180
 As 
SVR QSAR predict compound activities based on their molecular descriptors, it makes sense to 
cluster as well as to represent compounds in terms of molecular descriptors. By using a K-means 
method
179, 180
 and molecular descriptors computed from our own software,
181
 we generated 8,423 
compound families from the available compounds in the PubChem database that we were able to 
compute the molecular descriptors, which is consistent with the 12,800 compound-occupying 
neurons (regions of topologically close structures) for 26.4 million compounds of up to 11 
atoms,
182
 and the 2,851 clusters for 171,045 natural products.
183
  
The collected active compounds could be distributed in hundreds of the 8,423 families. The rest 
of the families could be taken as inactive datasets candidates and the inactive training dataset 
corresponding to each sparse or biased active training dataset was generated by random selection 
of 5~6 representative compounds from each of these “inactive” families and those active families 
with none of their members in the active training set. The remaining compounds of the “inactive” 
families in PubChem can be used as putative inactive testing sets. Because of the extensive effort 
in searching the known compound libraries for identifying active compounds in target classes, the 
number of undiscovered “active” families in PubChem database is expected to be relatively small, 
most likely no more than several hundred families. The ratio of the undiscovered “active” 
families (hundreds on less) and the families that contain no known active compound 
(7,000~8,000 based on current version of PubChem) for many target classes is expected to be 
<15%. Therefore, putative inactive compounds can be generated by extracting a few 
representative compounds of those families that contain no known active compound, with a 
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maximum possible “wrong” family representation rate of <15% even when all of the 
undiscovered active compounds are misplaced into the inactive class. 
2.2.2 Molecular descriptors 
Molecular descriptors are generated by a logic and mathematical procedure which transforms 
chemical information encoded within a symbolic representation of a molecule into a useful 
number or the result of some standardized experiment. They quantitatively represent structural 
and physicochemical features of molecules which enables the statistical analysis of chemical 
compounds. 
2.2.2.1 Definition and calculation of molecular descriptors  
Molecular descriptors have been extensively used in deriving structure-activity relationships,
184, 
185
 quantitative structure activity relationships,
186, 187
 and machine learning prediction models for 
pharmaceutical agents.
188-191
 A descriptor is “the final result of a logical and mathematical 
procedure which transforms chemical information encoded within a symbolic representation of a 












 and Xue descriptor set
197
 are available to calculate chemical descriptors. These 
methods can be used for deriving >3,000 molecular descriptors including constitutional 
descriptors, topological descriptors, RDF descriptors,
198














 2D autocorrelations, functional groups, atom-
centred descriptors, aromaticity indices,
205
 Randic molecular profiles,
206
 electrotopological state 
descriptors,
207
 linear solvation energy relationship descriptors,
208
 and other empirical and 
molecular properties. Not all of the available descriptors are needed for representing features of a 
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particular class of compounds. Moreover, without properly selecting the appropriate set of 
descriptors, the performance of a developed ML VS tool may be affected to some degrees 
because of the noise arising from the high redundancy and overlapping of the available 
descriptors. In this work, the Xue descriptor set and 98 1D and 2D descriptors were used. These 
98 descriptors were selected from the descriptors derived from MODEL program by discarding 
those that were redundant and unrelated to the problem studied here. The Xue descriptor set and 
these 98 descriptors are listed in Table 2.2 and Table 2.3. 
Table 2.2 Xue descriptor set generated by MODEL program 








Molecular weight, Number of rings, rotatable bonds, H-
bond donors, and H-bond acceptors, Element counts 
Molecular connectivity 
and shape  
28 
Molecular connectivity indices, Valence molecular 
connectivity indices, Molecular shape Kappa indices, 




Electrotopological state indices, and Atom type 
electrotopological state indices, Weiner Index, Centric 
Index, Altenburg Index, Balaban Index, Harary Number, 
Schultz Index, PetitJohn R2 Index, PetitJohn D2 Index, 
Mean Distance Index, PetitJohn I2 Index, Information 




Polarizability index, Hydrogen bond acceptor basicity 
(covalent HBAB), Hydrogen bond donor acidity (covalent 
HBDA), Molecular dipole moment, Absolute hardness, 
Softness, Ionization potential, Electron affinity, Chemical 
potential, Electronegativity index, Electrophilicity index, 
Most positive charge on H, C, N, O atoms, Most negative 
charge on H, C, N, O atoms, Most positive and negative 
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charge in a molecule, Sum of squares of charges on 
H,C,N,O and all atoms, Mean of positive charges, Mean of 
negative charges, Mean absolute charge, Relative positive 
charge, Relative negative charge  
Geometrical properties 25 
Length vectors (longest distance, longest third atom, 4th 
atom), Molecular van der Waals volume, Solvent 
accessible surface area, Molecular surface area, van der 
Waals surface area, Polar molecular surface area, Sum of 
solvent accessible surface areas of positively charged 
atoms, Sum of solvent accessible surface areas of 
negatively charged atoms, Sum of charge weighted solvent 
accessible surface areas of positively charged atoms, Sum 
of charge weighted solvent accessible surface areas of 
negatively charged atoms, Sum of van der Waals surface 
areas of positively charged atoms, Sum of van der Waals 
surface areas of negatively charged atoms, Sum of charge 
weighted van der Waals surface areas of positively 
charged atoms, Sum of charge weighted van der Waals 
surface areas of negatively charged atoms, Molecular 
rugosity, Molecular globularity, Hydrophilic region, 
Hydrophobic region, Capacity factor, Hydrophilic-
Hydrophobic balance, Hydrophilic Intery Moment, 
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Number of C,N,O,P,S, Number of total atoms, Number of  rings, 
Number of bonds, Number of non-H bonds, Molecular weight,, 
Number of rotatable bonds, number of H-bond donors, number of 
H-bond acceptors, Number of 5-member aromatic rings, Number 
of 6-member aromatic rings, Number of N heterocyclic rings, 
Number of O heterocyclic rings, Number of S heterocyclic rings. 
Chemical 
properties 





Schultz molecular topological index, Gutman molecular 
topological index, Wiener index, Harary index, Gravitational 
topological index, Molecular path count of length 1-6, Total path 
count, Balaban Index J, 0-2th valence connectivity index, 0-2th 
order delta chi index, Pogliani index, 0-2th Solvation connectivity 
index, 1-3th order Kier shape index, 1-3th order Kappa alpha 
shape index, Kier Molecular Flexibility Index, Topological radius, 
Graph-theoretical shape coefficient, Eccentricity, Centralization, 




Sum of Estate of atom type sCH3, dCH2, ssCH2, dsCH, aaCH, 
sssCH, dssC, aasC, aaaC, sssC, sNH3, sNH2, ssNH2, dNH, ssNH, 
aaNH, dsN, aaN, sssN, ddsN, aOH, sOH, ssO, sSH; Sum of Estate 
of all heavy atoms, all C atoms, all hetero atoms, Sum of Estate of 
H-bond acceptors, Sum of H Estate of atom type HsOH, HdNH, 
HsSH, HsNH2, HssNH, HaaNH, HtCH, HdCH2, HdsCH, HaaCH, 
HCsats, HCsatu, Havin, Sum of H Estate of H-bond donors 
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2.2.2.2 Scaling of molecular descriptors 
Chemical descriptors are normally scaled before they can be employed for machine learning. 
Scaling of chemical descriptors ensures that each descriptor has an unbiased contribution in 
creating the prediction models.
209
 Scaling can be done by number of ways e.g. auto-scaling, range 
scaling, Pareto scaling,
210
 and feature weighting.
209
 In this work, range scaling is used to scale the 
chemical descriptor data. Range scaling is done by dividing the difference between the descriptor 
value and the minimum value of that descriptor with the in range of that descriptor:  
                                                    
       
         
           
                                        (1) 
Where     
      ,   , dj,max and dj,min are the scale descriptor value of compound i, absolute 
descriptor value of compound i , maximum and minimum  values of descriptor j respectively. The 
scaled descriptor value falls in the range of 0 and 1. 
2.2.3 Support Vector Regression (SVR) method 
Given the compounds with their activity data and molecular descriptors, a regression model for 
QSAR can be constructed using SVR to estimate the targeted values. Following is a description 
explaining how SVR works. 
Suppose we are given training data       ll yxyx ,,,, 11  , where   denotes the space of 
the input patterns (molecular descriptors derived from structures of compounds as in this study). 
In ε-SVR,211 our goal is to find a function  xf  that has at most ε deviation from the actually 
obtained targets iy  for all the training data, and at the same time is as flat as possible. In other 
words, SVR constructs a “tube” with the radius of ε to involve as many training points in it. In 
linear cases, the function f could be written as 
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 ( )  〈   〉                                                         (2) 
Where 〈   〉 denotes the dot product in χ. Flatness in the case of (2) means that one seeks a 
small ω. One way to ensure this is to minimize the norm, i.e. ‖ ‖  〈   〉. We can write this 






















The tacit assumption in (3) was that such a function f actually exists that approximates all pairs 
 ii yx ,  with ε precision, or in other words, that the convex optimization problem is feasible. 
Sometimes, however, this may not be the case, or we also may want to allow for some errors. 
Analogously to the “soft margin” loss function, one can introduce slack variables 
*, ii   to cope 
with otherwise infeasible constraints of the optimization problem (3). Hence we arrive at the 




































The constant C > 0 determines the trade-off between the flatness of f and the amount up to which 
deviations larger than ε are tolerated. The formulation above corresponds to dealing with a so 
called ε–insensitive loss function 

  described by  















:                                              (5) 
Figure 2.5 depicts the situation graphically. Only the points outside the shaded region contribute 
to the cost insofar, as the deviations are penalized in a linear fashion. It turns out that the 
optimization problem (4) can be solved more easily in its dual formulation. Moreover, the dual 
formulation provides the key for extending SVR to non-linear functions. Hence a standard 
dualization method utilizing Langrange multipliers will be used.  
 
Figure 2.5 The soft margin loss setting corresponds for a linear Support Vector Regression  
 
The key idea is to construct a Lagrange function from both the objective function and the 
corresponding constraints, by introducing a dual set of variables. It can be shown that this 
function has a saddle point with respect to the primal and dual variables at the optimal solution. 
Hence we proceed as follows: 













:   









**** ,                            (6) 
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It is understood that the dual variables in (6) have to satisfy positivity constraints, i.e. 
0,,, ** iiii  . It follows from the saddle point condition that the partial derivatives of L with 
respect to the primal variables  *,,, iib   have to vanish for optimality.  
  0
1
*   
l
i iib
L                                                      (7)  
  0
1
*   
l
i iii
xL                                           (8) 
 





                                                          (9) 
Substituting (7), (8), and (9) into (6) yields the dual optimization problem.  
Maximize 
  

























































In deriving (10), the dual variables 
*, ii   have already been eliminated through condition (9), as 
these variables did not appear in the dual objective function anymore but only were present in the 









And therefore  
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* ,                                           (11) 
This is the so-called Support Vector expansion, i.e.   can be completely described as a linear 
combination of the training patterns ix . In a sense, the complexity of a function’s representation 
by support vectors is independent of the dimensionality of the input space  , and depends only 
on the number of support vectors. Moreover, the complete algorithm can be described in terms of 
dot products between the data.  
Meanwhile, b can be computed by exploiting the so called Karush-Kuhn-Tucker (KKT) 
conditions. These state that at the optimal solution the product between dual variables and 

























                                                      (13) 












                                         (14) 
After the determination of   and b, the targeted values iy  can be estimated from a given vector
 .  
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In non-linear regression cases, which frequently occur in QSAR model construction involving 
diverse structures, SVR maps the input vectors into a higher dimensional feature space by using a 
kernel function  ii yxK , . The mapping mechanism of SVR is constant with the cases in SVM 
that have been extensively described in previous literature.
212, 213
 Thus the details would be 
skipped here. The kernel function used in this study is the RBF kernel, which has been 









                                                      (15) 
Linear SVR can then applied to this feature space based on the following decision function: 





* ,                                        (16) 
2.2.4 Tanimoto similarity searching method  




                              (17)
 
 
where l is the number of molecular descriptors. A compound i is considered to be similar to a 
known active j in the active dataset if the corresponding sim(i,j) value is greater than a cut-off 
value. In this work, the similarity search was conducted for MDDR compounds. Therefore, in 
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MDDR compounds. The cut-off values for similarity compounds are typically in the range of 0.8 
to 0.9.
218, 219
 A stricter cut-off value of 0.9 was used in this work. 
2.2.5 Model validation and virtual screening performance evaluation 
Derived from application of statistical tools correlating biological activity of chemicals with 
descriptors representative of molecular structure and/or properties, QSAR models can then be 
adapted for lead optimization and modification, and virtual screening large chemical database for 
novel drug hits. Obtaining a good quality QSAR model depends on many factors, such as the 
quality of biological data as described in Section 2.1.1, the choice of descriptors and statistical 
methods. Any QSAR modeling should ultimately lead to statistically robust models capable of 
making accurate and reliable predictions of biological activities of new compounds. In this work, 
the QSAR models are evaluated by adopting three strategies: internal 5-fold cross-validation, 
external test validation and evaluation on performance for large chemical database virtual 
screening.  
2.2.5.1 Internal 5-fold cross-validation 
In 5-fold cross-validation, the curated collection of compounds is randomly partitioned into 5 
subsets. Of the 5 subsets, each single subset is retained as the validation data for testing the model, 
and the remaining 4 subsets are used as training data. The cross-validation process is then 
repeated for 5 times. The squared cross-validation correlation coefficient Q
2
 is employed for 
evaluating the internal predictivity of QSAR models. 
     
∑(    ̂ )
 
∑(    ̅) 
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where    is the experimentally observed activity for each compound,  ̂  is the in-silico determined 
activity from cross-validation, and  ̅ is the averaged observed activity of all compounds included 
in all the 5 folds. 
2.2.5.2 External/independent test validation 
In a very important review paper entitled “Beware of q2!”220 Golbraikh and Tropsha demonstrated 
that the high accuracy of the traning set model characterized with leave-one-out (LOO) or leave-
some-out cross validated q
2
 is not indicative of the high external predictive power of the model. 
Thus QSAR models exclusively relying on training set modeling without any external validation 
are bad at generalization and considered to be unreliable.  
In developing our SVR QSAR model, a hard margin C=1,000 was used and the predictivity of the 
model on external test set is evaluated by the Correlation Coefficient (R) and Mean Squared Error 
(MSE).  






































































where iy  is the actual activity measured by experiments in testing datasets, iyˆ  denotes the 
estimated value and n is the total number of compounds in testing dataset. 
2.2.5.3 Performance evaluation on large chemical database virtual screening 
The typical measurements of a model performance in screening large libraries include
221
 yield 
(percentage of known positives predicted as virtual hits), hit-rate (percentage of virtual hits that 
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are known positives), false hit-rate (percentage of virtual hits that are known negatives) and 
enrichment factor EF (magnitude of hit-rate improvement over random selection): 
                  (  )  
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2.2.6 Overfitting problem and its detection 
Overfitting is a major concern in machine learning regression methods. It happens when a model 
that agrees well with the observed data but has no predictive ability, which means it does not have 
any value to unseen or future data. There are two main types of overfitting situations: (1) a model 
more flexible than it needs to be and (2) a model including irrelevant descriptors.
222
 An over-
fitted classification system tends to obtain much higher prediction accuracies in the cross-
validation sets than in the independent validation sets. Hence frequently used method for 
checking whether a model is overfitted is to compare the prediction accuracies in the cross-
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CHAPTER 3 Development of Pathway Cross-talk Database 
Facilitating Multi-target Selection 
Cross-talk between pathways plays important regulatory roles in biological processes, disease 
processes, and therapeutic responses. Knowledge of these cross-talks is highly useful for 
facilitating systems level analysis of diseases, biological processes and the mechanisms of multi-
targeting drugs and drug combinations. However, to our best knowledge, currently no such 
database exists providing this kind of information. Developed in the year of 2008, the Pathway 
Cross-talk Database (PCD) provides information about experimentally discovered cross-talks 
between pathways and their relevance to diseases and biological processes, mechanism of multi-
target drugs and drug combinations. In this chapter, the data source, structure and access of PCD 
are introduced in details. The usefulness of PCD in facilitating systems level studies of diseases 
and mechanism of drug combinations and multi-targeting drugs is demonstrated by the analysis 
of the effect of glutamate on glioma cell invasion, the synergistic actions of tamoxifen-herceptin 
drug combination, and multi-targeting cross-talked signaling pathways, e.g. EGFR-VEGFR, 
EGFR-PDGFR, EGFR-FGFR and EGFR-Src pathways, as the prospective direction for treating 
non-small cell lung cancer (NSCLC). 
3.1 Introduction 
Biological pathways are part of biological systems that play context-dependent and specific 
metabolic and signal transduction tasks, and cross-talks between these pathways facilitate the 
regulation and coordination of biomolecular events in biological, disease, and therapeutic 
processes in responses to internal changes, external stimuli, and actions of therapeutic agents.223-
225 Individual pathways alone cannot fully represent signaling networks of the cell and methods 
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for collective analysis of the dynamics of multiple network elements have been developed.226, 227 
None-the-less, individual pathway concept and the relevant models are useful building blocks for 
more comprehensive understanding of network collective actions, and knowledge of pathway 
cross-talks further facilitates and extends the use of the pathway concept for studying 
biological228-230 and disease231-237 processes, for discovering multi-targeting drugs and drug 
combinations,1, 18, 123, 238, 239 and for simulating and theoretically investigating the biological 
events.240, 241 
A number of pathway databases have been developed to provide comprehensive information 
about the molecular interactions and networks of a variety of metabolic, transport, and signaling 
pathways.242-246 Experimental studies have shown the existence of cross-talk between many 
different pathways. Our search of literature identified 137 experimentally discovered pathway 
cross-talks among 89 pathways or pathway components with sufficient information about the 
molecular interactions or regulations that mediate these cross-talks. The relevant information has 
not been specifically provided in the existing pathway databases. Databases of protein functional 
association networks such as STRING247 and Reactome248 are useful resources for assessing 
interactions that may mediate some of the reported cross-talks, However, these databases are not 
specifically designed for convenient access of cross-talk interactions, and some of the 
interactions, particularly those via regulation of protein levels, have not been included in these 
databases.  
A public resource for providing the relevant information about these and other pathway cross-
talks is helpful in complementing and expanding the application scope of the existing pathway 
and protein association databases. A new database, Pathway Cross-talk Database (PCD), was 
introduced as a public resource of experimentally discovered pathway cross-talks. PCD provides 
detailed description about cross-talking partners, their mediators in terms of molecular 
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interactions or regulations, cross-talk effects, related diseases or biological processes, and 
relevant references. Pathway maps and graphical representation of the cross-talks are provided in 











 and Cell Signaling Technology,
252
 are provided to further facilitate the access of 
network maps and other information. 
3.2 Database information source, structure and access 
PCD has a web interface at http://bidd.nus.edu.sg/group/PCD/PCD.asp, which is shown in Figure 
3.1. The entries of this database were generated from a comprehensive search of published 
literature via PubMed by using a similar search and inspection procedure as we have used for 
developing databases of functional proteins and effects.253-257 We used the keyword “crosstalk” 
combined with either “pathway” or “network” or “protein” to identify the literature that describe 
experimentally discovered cross-talk between two different pathways. A total of 650, 170, and 
1,022 abstracts were obtained by the keyword search, which were reduced to 447 entries after 
removing redundant and irrelevant entries. Irrelevant entries are those describing inter-cellular, 
inter-tissue, or intra-pathway cross-talks. These 447 literature were further inspected manually to 
select 137 entries with sufficiently detailed information about the molecular interactions or 
regulations mediating the cross-talk. Members of each pathway were retrieved from Ambion251 
and Biocarta258 databases, and the corresponding protein and gene IDs were retrieved from 
SwissProt database.250 
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Figure 3.1 Web-page of PCD 
PCD is browseable and searchable via the names and list of cross-talk pathways or pathway components 
and via the names and list of disease or biological processes provided in the PCD webpage. Download and 
keyword search are also supported via download link and keyword search window in the webpage. 
 
The cross-talk entries are browseable and searchable via the names and list of cross-talk pathways 
or pathway components and via the names and list of disease or biological processes provided in 
the PCD webpage (Figure 3.1). Download and keyword search are also supported via download 
link and keyword search window in the webpage. The result of a typical search is illustrated in 
Figure 3.2, in which all cross-talks that satisfy the search criteria are listed. This list includes the 
names of the cross-talk pathways and links to each cross-talk entry. These entries can be ordered 
by name of cross-talk partner (pathway), disease name, and PCD entry ID. The detailed 
information related to a distinct entry can be obtained by clicking the PCD entry ID of a selected 
cross-talk.  The page of a cross-talk entry, as shown in Figure 3.3, provides detailed description 
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about the names of cross-talk pathways or pathway components, cross-talk mediator in terms of 
molecular interactions or regulations, cross-talk effect, related diseases or biological processes, 
literature descriptions, related references, and cross-talk map (an example can be seen in Figure 
3.4). Further information about the maps and protein members of the cross-talk pathways can be 
obtained by clicking the name of the respective pathway. As shown in Figure 3.5, the 
corresponding pathway information page provides the pathway map and links to one or more of 






 and Cell Signaling Technology
252
 in 
which further information of the pathway is available. Enzyme or protein information such as 
enzyme name and catalyzed reaction or protein name, gene name, SwissProt accession number, 
and amino acid sequence for each member of the pathway or pathway component can also be 
retrieved by clicking the corresponding component block in the map. 
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Figure 3.2 The interface for a search in PCD 
All entries that match the search selection are listed. This list includes the name of cross-talk partners, brief 
description of cross-talk effects, related diseases or biological processes, and entry access to the detailed 
cross-talk information. 




Figure 3.3 Cross-talk information page 
This page provides information about cross-talk partners, cross-talk mediator in terms of molecular 
interactions or regulations, cross-talk effect, related diseases or biological processes, the detailed 
description in literature and references as well as the graphical representation of the cross-talk. Further 








Figure 3.4 An example of graphical representation for pathway cross-talk. Cross-talk between Arachidonic acid metabolism and PPAR signaling pathway 




Figure 3.5 Pathway information page 
Pathway maps and links to other four common-used pathway databases – KEGG, Cell Signaling 
Technology, Ambion, and BioCarta – have been provided for each pathway covered by PCD. Detailed 
information for each member of the pathway or pathway component can also be retrieved by clicking the 
corresponding component block in the map. 
 
3.3 Potential applications of PCD 
3.3.1 Systems level analysis of diseases  
One potential application of PCD in facilitating systems level study of diseases can be illustrated 
by the analysis of recently discovered effects of glutamate signaling in promoting glioma cell 
invasion.
259
 Malignant gliomas have been shown to release glutamate that kills surrounding brain 
cells, creating room for tumor expansion. This glutamate release occurs primarily via system xC, 
a Na+-independent cystine-glutamate exchanger. The released glutamate also acts as an essential 
autocrine/paracrine signal that promotes cell invasion.
259
 The mechanism of glutamate promotion 
of cell invasion can be partly explained by the cross-talk between Ca2+-permeable AMPA 
receptor pathway and PI3K-AkT Pathway. In Bergmann glia, glutamate binding to Ca2+-
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permeable AMPA receptors leads to receptor tyrosine phosphorylation, which subsequently 
interacts and activates PI3K, activated PI3K then activates AkT leading to the promotion of cell 
invasion.
260
 Therefore, Akt functions as downstream effectors for Ca2+-signaling mediated by 
AMPA receptor in glioblastoma cells. AkT activation via the cross-talk between glutamate-
AMPA receptor pathway and PI3K-Akt pathway may contribute to the high degree of anaplasia 
and invasive growth of human glioblastoma.
261
 
3.3.2 Systems level analysis of synergistic drug combinations 
The potential application of PCD can be further illustrated by the analysis of literature-reported 
synergistic drug combinations. Tamoxifen-Trastuzumab (Herceptin) combination has been found 
to synergistically inhibit the growth in ER- positive, HER-2/neu overexpressing BT-474 breast 
tumor cells.
262, 263
 Tamoxifen is an estrogen receptor (ER) antagonist
264
 and herceptin is an anti-
HER-2/neu antibody
265
 extensively used for the treatment of breast cancers. The synergistic 
actions of this drug combination can be partly explained by their collective regulation of the 
cross-talk between estrogen receptor pathway and HER2 signaling. HER2 is known to activate 
p42/44 MAPK, which subsequently activates ER and ER coactivator AIB1.
266-268
 Moreover, ER 
directly interacts with HER2 in the membrane to transactivate HER2 and its signaling.
269
 Apart 
from inhibiting HER-2 signaling, the anti-HER-2/neu antibody herceptin stops HER-2/neu 
induced activation of ER and AIB1. On the other hand, ER antagonist tamoxifen stops ER 
induced transactivation of HER-2, leading to synergistic actions. 
3.3.3 Systems level analysis of multi-targeting drugs and multi-target selection 
Another potential application of PCD can be illustrated by the systems level study of multi-target 
agents to achieve enhanced therapeutic efficacies and reduced drug resistance activities by 
targeting multiple interacted signaling pathways. One example can be demonstrated by the 
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necessity of the collective inhibition of EGFR and VEGFR signaling pathways in treating non-
small cell lung cancer (NSCLC). NSCLC is the most common type of lung cancer that is 
responsible for the highest number of cancer deaths.
270
 Because lung cancer is typically 
diagnosed at an advanced stage, the prognosis and survival rate for patients are poor and have 
remained not improved for decades.
271
 Targeted inhibition of either EGFR or VEGFR signaling 
pathways has been clinically validated in advanced NSCLC with a number of approved drugs e.g. 
bevacizumab (Avastin), erlotinib (Tarceva), cetuximab (Erbitux) and gefitinib (Iressa). However, 
in some cases, these drugs exhibit moderate efficacies, undesired AEs and resistance profiles.
2
 
The acquired resistance can be partially attributed to the cross-talks between EGFR and VEGFR 
signaling pathways in which the VEGF can be up-regulated independent of EGFR signaling thus 
promoting tumor angiogenesis.
2, 6, 10
 The detailed description of one possible mechanism can be 
found in Section 1.1.1.  
Besides, the reduced sensitivity to EGFR inhibitors in NSCLC patients may also be linked to 
acquired alternative routes of proliferative and survival signaling, e.g. PDGFR and FGFR, 
bypassing EGFR signaling.
272
 PDGFR and FGFR are aberrantly expressed in mesenchymal-like 
NSCLC cells.
272
 The autophosphorylation and substrate-phosphorylation of PDGFR has been 
shown to be significantly increased when EGFR was inhibited.
272
 Evidence also showed that 
FGFR inhibition had an effect on ERK signaling and to a lesser extent on Akt signaling in two 
mesenchymal-like NSCLC cell lines, H1703 and H226, which were growth inhibited when 
treated with FGFR inhibitors. These findings suggested that, via PDGFR and FGFR, the 




Another kinase, Src, has been reported to be increased expressed in 50% of squamous cell 
carcinomas isolated from patients with NSCLC.
272
 In addition, high levels of Src kinase activity 
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have also been reported in NSCLC correlating with enlarged tumor size.
151
 Constitutive activation 
of EGFR is found in a subset of NSCLC tumors that are dependent on EGFR for survival.
148
 
Besides EGFR, kinase Src also offers a promising target for treating NSCLC since the inhibition 
of it can lead to the inhibition of multiple signaling pathways including those mediated by 
EGFR.
148
 One possible path is Src activation of EGFR by phosphorylating tyrosine residue Y845 
to promote oncogenesis via STAT-5b independent of the ERK2 pathway.
149, 150, 152
 And the 
synergistic effect of EGFR and Src in promoting aggressive phenotype has been evidenced in 
nude mice that tumors in nude mice inoculated with EGFR/Src overexpressing fibroblasts were 




Therefore, collective blockade of interactive cross-talked signaling pathways or key components 
of these pathways, e.g. EGFR-VEGFR, EGFR-PDGFR, EGFR-FGFR and EGFR-Src, may offer 
the treatment for NSCLC with enhanced therapeutic effects. In Chapter 5, a novel high 
throughput SVR QSAR approach is developed and used for searching dual inhibitors of these 
kinase combinations.  
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CHAPTER 4 Construction of QSAR Models with Enhanced 
Ability for Searching Highly Novel Hits 
Based on a new chemspace-wide regression strategy, in this chapter, we developed support vector 
regression (SVR) QSAR models applicable beyond similarity-based applicability domains. In 
screening large chemical libraries, these QSAR models built from pre-2010 DHFR, ACE and 
Cox2 inhibitors showed substantial predictive capability for post-2010 and patented inhibitors 
outside the domains, while performed equally well  for inhibitors within the domains as the 
established QSAR methods. 
4.1 Introduction 
Apart from drug lead optimization, QSAR models have been developed for searching drug leads, 
particularly novel ones, from large chemical libraries.
130-137
 These models achieve good hit rates 
and activity assessment by pharmacophoric-shim adjusted molecular docking (PSA-Docking),
130-
132
 Bayesian-based target-family activity profiling (BTFAP),
133
 and machine learning regression  
(MLR) of known actives
134-137
 within applicability domains (ADs) defined by binding-mode 
constraints,
130
 Baysian active-inactive boundaries,
133, 138
 and range-based and distance-based 
similarity to the known actives.
139, 140
 In particular, MLR requires no knowledge of target 3D 
structure or target-family activity profiles,
141
 but cannot find highly novel actives outside 
similarity-based ADs. In this work, we extended an approach in the BTFAP method
133
 for 
constructing new MLR QSAR models via chemspace-wide activity regression aimed at finding 
highly novel inhibitors without compromising hit rates within similarity-based ADs. Our 
consensus QSAR models developed by “old” (pre-2010) DHFR, ACE and Cox2 inhibitors 
performed well in predicting the activities of “new” (post-2010) inhibitors with R2 values 
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 methods, and in 
identifying inhibitors from large chemical libraries (168,016 MDDR and 13.56 million PubChem 
compounds) at improved hit rats and enrichment factors. In particular, our method showed some 
level of capability in the identification and activity assessment of highly novel inhibitors outside 
similarity-based ADs. 
4.2 Materials and methods 
4.2.1 Compound collection, training and testing datasets, molecular descriptors 
Chemically diverse sets of 760, 803 and 2,467 DHFR, ACE and Cox2 inhibitors (pIC50>5)  and 
200, 127 and 618 non-inhibitors (pIC50≤5) published before 2010 were collected from the 
ChEMBL database
158
 and additional literature search,
164
 which were tentatively regarded as “old” 
inhibitors and non-inhibitors and used for developing QSAR models. From the ChEMBL 
database, we collected additional sets of 26, 47 and 72 DHFR, ACE and Cox2 inhibitors and 46, 
54 and 50 non-inhibitors published since 2010, which were tentatively regarded as “new” 
inhibitors and used for testing QSAR models. Moreover, the MDDR database contains 167, 532 
and 990 DHFR, ACE and Cox2 inhibitors not found in the ChEMBL database, which together 
with the rest of the 168K MDDR compounds and 13.56 million compounds from the PubChem 
database
273
 were used for testing the ability of QSAR models in the virtual screening (VS) of 
large chemical libraries. By using the Chembench web-based tool
274
 for QSAR modeling and 
prediction with the parameters adjusted to reproduce the results of the published HDAC inhibitor 
QSAR screening studies,
137
 we found that 0.00%, 12.77% and 18.06% of the post-2010 and 
14.97%, 32.89% and 5.15% of the patented DHFR, ACE and Cox2 inhibitors and 8.70%, 62.96% 
and 14.00% of the post-2010 non-inhibitors are outside the similarity-based ADs derived by the 
method of the Tropsha group
134, 137
 with respect to the pre-2010 inhibitors and non-inhibitors, 
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suggesting that substantial percentage of the “new” inhibitors are highly novel ones outside the 
typical similarity-based ADs. 
While conventional MLR QSAR models are applicable within specific ADs,
275
 a method for 
extending the applicability of MLR QSAR models beyond similarity-based ADs has been 
outlined by Martin et al in their profile-QSAR modeling of kinase inhibitory activities.
133
 In their 
method,
133
 actives of an individual target are divided into specific activity ranges, within each 
range a Bayesian classification model is developed from the in-range actives and combination of 
the out-range actives and chemically diverse inactives,
138
 a Bayesian QSAR model is 
subsequently constructed based on the experimental activity values of the compounds (pIC50>4) 
and a uniformly assigned activity value (pIC50=3) for all inactives with pIC50≤3 or unknown 
values. The inclusion of chemically diverse inactives helps refining active-inactive boundaries for 
enhanced identification of highly novel actives.
138, 164
 In this work, we further improved Martin et 
al’s method in three aspects. The first is the significant expansion of the inactive chemspace from 
one corporate archive (1.5 million) to all Pubchem and MDDR compounds (13.7 million). The 
second is the chemspace-wide regression of compounds by a single MLR directly based on 
experimental (for actives) and assigned (for inactives) activity values without dividing actives 
into specific activity ranges. The third is the assignment of the activity values of putative 
inactives based on the distance-dependent activity profiles revealed by the regression of the 
experimental activity values of the known inactives with respect to their closest distances to the 
known potent actives, instead of assignment of a uniform activity value.   
For each target, putative inactives covering Pubchem and MDDR compounds were generated by 
using our previously-reported method that requires no knowledge of known inactives or actives 
of other target classes.
164, 276
 The 13.56M PubChem and 168K MDDR compounds were clustered 
into 8,423 compound families by using molecular descriptor Tanimoto similarity coefficients
217
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where {xdi, d=1, …, l } are molecular descriptors for the i-th compound computed, and the 
molecular descriptors were computed from the MODEL194 program. The detailed description 
of these molecular descriptors can be found in Section 2.2.2. 
Our collected DHFR, ACE and Cox2 inhibitors are in 76, 188 and 901 families respectively. The 
numbers of families without a known DHFR, ACE and Cox2 inhibitor are 8,347, 8,235 and 7,522 
respectively, which is consistent with the number of 12,800 compound-occupying neurons 
(regions of topologically close structures) for 26.4M compounds of up to 11 atoms
277
 and that of 
the 2,851 structural clusters for 171,045 natural products.
278
 By selecting one representative 
compound from each family containing no known inhibitor as a putative inactive, we obtained 
8,347, 8,235 and 7,522 putative inactives for representing the inactive chemspace of PubChem 
and MDDR compounds, which were used for training MLR QSAR models. Some new inhibitors 
are likely distributed in the families whose representative is regarded as a putative inactive, a 
substantial percentage of these new inhibitors are expected to be identifiable as hits even if their 
family representatives are regarded as inactives.
164
  
To assign activity values of the putative inactives, we derived the distance-dependent pIC50 
regression profiles of the 30, 68 and 111 known DHFR, ACE and Cox2 non-inhibitors 
(2<pIC50<4) with respect to their closest distances to the 282, 492 and 759 known potent 
inhibitors (pIC50>7) from their experimental activity values and molecular fingerprint Tanimoto 
similarity coefficients (Figure 4.1-4.3), with molecular fingerprints computed by using 
PaDEL.
279
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were assigned based on their closest distances to the 282, 492 and 759 known potent inhibitors, 
which are in the range of 2.87-3.67, 2.48-3.66 and 3.01-3.74 with median values of 3.32, 3.22 and 




Figure 4.1 The pIC50 values of the known DHFR non-inhibitors (2<pIC50<4) with respect to their closest 
distances to the known potent inhibitors  





















Fingerprints Tanimoto to potent inhibitors 
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Figure 4.2 The pIC50 values of the known ACE non-inhibitors (2<pIC50<4) with respect to their closest 
distances to the known potent inhibitors  
 
Figure 4.3 The pIC50 values of the known Cox2 non-inhibitors (2<pIC50<4) with respect to their closest 
distances to the known potent inhibitors 
 




















Fingerprints Tanimoto to potent inhibitors 




















Fingerprints Tanimoto to potent inhibitors 
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4.2.2 Computational models 
We used a MLR method, support vector regression (SVR), for deriving QSAR models not only 
because it has consistently shown good performance,
135, 280-285
 but also because it is less penalized 
by sample redundancy and has lower risk for over-fitting.
286, 287
 The latter is particularly important 
for chemspace-wide regression. Given a training dataset     ll yxyx ,,,, 11  , where xi is the input 
vector composed of molecular descriptors of compound i and yi is its activity value, the objective 
of ε-SVR211 is to find a function  xf  that minimally deviates from the activity values { iy } of 
the training compounds (with deviation amplitude less than ε), i.e., it constructs a tube of radius 
of ε to maximally include training compounds. In linear regression 







where 0i  are Lagrange multipliers. In non-linear regression, which frequently occur in 
developing QSAR from chemically diverse compounds, SVR maps the input vectors into a higher 
dimensional feature space by using a kernel function  ii yxK , . The kernel function used in this 
study is the RBF kernel, 
 
which has been extensively used and consistently shown better performance than other kernel 
functions.
214-216
 Linear SVR can then be applied to this feature space based on the following 
decision function. 





* ,  
2 2/ 2
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More mathematical details about the SVR method can be found previously in Section 2.2.3. The 





 a hard margin C=1,000, and ε =0.19-0.60. 
4.3 Results and discussion 
4.3.1 Performance of SVR QSAR models in identification of DHFR, ACE and Cox2 
inhibitors based on 5-fold cross validation test 
The QSAR models for DHFR, ACE and Cox2 inhibitors were trained and tested by using 5-fold 
cross validation (5-fold CV) method. For each target, training inhibitors and non-inhibitors were 
randomly divided into 5 groups of approximately equal size, with 4 groups used for training an 
SVR model and 1 group used for testing it, and the process was repeated for all 5 possible 
training-testing configurations. The squared correlation coefficient 
     
∑(    ̂ )
 
∑(    ̅) 
 
was used for preliminary performance evaluating of the QSAR models, where    and  ̂  are the 
actual and predicted activity value of compound i, and  ̅ is the average predicted activity value of 
all compounds over all 5 folds. For each target, the top 15 SVR QSAR models with the best 5-
fold CV performance (Table 4.1-4.3) were used for constructing a consensus SVR QSAR model 
for testing their ability in identifying “new” inhibitors from large chemical libraries. For 
comparison, consensus kNN QSAR models for DHFR, ACE and Cox2 inhibitors were developed 
by using the same sets of training compounds and Chembench with the parameters adjusted to 
reproduce the results of the published HDAC inhibitor QSAR screening studies.
137
 For each 
target, the Chembench generated kNN QSAR models with the best performance against the 5-
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fold CV testing compounds (Table 4.4) were used as a consensus kNN QSAR model for 
comparison with our consensus SVR model.  
The R
2 
values of our SVR QSAR models in the 5-fold CV tests are in the range of 0.51-0.81, 
0.43-0.85 and 0.45-0.79 for DHFR, ACE and Cox2 inhibitors respectively, which are comparable 
to the R
2 
values (0.55-0.60, 0.60-0.61 and 0.80-0.86) of the Chembench generated kNN QSAR 
models tested on the same sets of inhibitors and non-inhibitors, and close to the reported average 
R
2
 values of the PSA-Docking (0.6-0.8)
130-132
 and the BTFAP (0.6)
133
 methods for kinase 
inhibitors that have been randomly divided into 75/25 training and testing sets. The 75/25 split is 
very similar to our 5-fold CV set-up. Hence, the results by both testing methods may be 
reasonably compared with each other. These R
2 
values are significantly above the success 
criterion of 0.32 derived from an extensive study of docking methods.
289
 Therefore, our method 




Table 4.1 The 5-fold cross validation performance of the top-15 SVR QSAR models for predicting DHFR inhibitors  
Model No. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 
Epsilon 0.21 0.22 0.23 0.23 0.24 0.25 0.26 0.27 0.26 0.27 0.28 0.29 0.30 0.31 0.32 






1 0.8059 0.8068 0.8076 0.7929 0.7936 0.7940 0.7943 0.7949 0.7810 0.7816 0.7823 0.7831 0.7838 0.7843 0.7847 
2 0.7894 0.7905 0.7916 0.7754 0.7766 0.7775 0.7783 0.7791 0.7637 0.7645 0.7649 0.7655 0.7666 0.7673 0.7677 
3 0.7873 0.7875 0.7875 0.7744 0.7746 0.7747 0.7749 0.7751 0.7619 0.7623 0.7625 0.7627 0.7627 0.7629 0.7631 
4 0.7903 0.7906 0.7909 0.7800 0.7810 0.7813 0.7813 0.7815 0.7695 0.7703 0.7710 0.7714 0.7717 0.7719 0.7719 






1 0.5076 0.5079 0.5079 0.5071 0.5079 0.5085 0.5082 0.5074 0.5100 0.5088 0.5075 0.5072 0.5065 0.5054 0.5046 
2 0.5660 0.5655 0.5648 0.5592 0.5598 0.5599 0.5592 0.5580 0.5529 0.5537 0.5530 0.5520 0.5514 0.5503 0.5490 
3 0.5836 0.5875 0.5921 0.5796 0.5848 0.5892 0.5935 0.5967 0.5826 0.5890 0.5926 0.5947 0.5961 0.5961 0.5972 
4 0.5591 0.5592 0.5585 0.5528 0.5528 0.5529 0.5533 0.5539 0.5487 0.5491 0.5486 0.5479 0.5470 0.5468 0.5477 
5 0.5358 0.5384 0.5398 0.5407 0.5394 0.5381 0.5374 0.5376 0.5389 0.5387 0.5383 0.5372 0.5352 0.5360 0.5364 
Predictive q
2




1 0.9980 0.9981 0.9980 0.9981 0.9981 0.9981 0.9981 0.9981 0.9983 0.9983 0.9982 0.9981 0.9981 0.9981 0.9981 
2 0.9982 0.9981 0.9981 0.9982 0.9981 0.9981 0.9981 0.9981 0.9982 0.9982 0.9982 0.9982 0.9981 0.9981 0.9981 
3 0.9983 0.9983 0.9983 0.9982 0.9982 0.9982 0.9982 0.9982 0.9983 0.9982 0.9982 0.9982 0.9983 0.9982 0.9982 
4 0.9982 0.9982 0.9982 0.9982 0.9982 0.9982 0.9982 0.9982 0.9983 0.9982 0.9982 0.9981 0.9982 0.9982 0.9982 
5 0.9983 0.9983 0.9983 0.9985 0.9984 0.9983 0.9983 0.9982 0.9984 0.9983 0.9983 0.9983 0.9983 0.9983 0.9983 
Average 0.9982 0.9982 0.9982 0.9982 0.9982 0.9982 0.9982 0.9982 0.9983 0.9982 0.9982 0.9982 0.9982 0.9982 0.9982 
  
  
Table 4.2 The 5-fold cross validation performance of the top-15 SVR QSAR models for predicting ACE inhibitors  
Model No. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 
Epsilon 0.47 0.48 0.52 0.53 0.54 0.55 0.56 0.57 0.58 0.59 0.60 0.53 0.54 0.55 0.56 






1 0.8043 0.8039 0.8322 0.8313 0.8304 0.8249 0.8285 0.8277 0.8270 0.8262 0.8254 0.8151 0.8142 0.8133 0.8122 
2 0.8143 0.8139 0.8471 0.8459 0.8446 0.8434 0.8422 0.8410 0.8398 0.8386 0.8373 0.8282 0.8272 0.8262 0.8250 
3 0.8093 0.8089 0.8435 0.8425 0.8415 0.8404 0.8393 0.8381 0.8369 0.8356 0.8341 0.8240 0.8232 0.8224 0.8215 
4 0.8223 0.8218 0.8470 0.8456 0.8443 0.8428 0.8413 0.8397 0.8382 0.8367 0.8353 0.8336 0.8327 0.8317 0.8307 






1 0.5271 0.5268 0.5558 0.5581 0.5601 0.5614 0.5625 0.5631 0.5636 0.5640 0.5641 0.5404 0.5420 0.5433 0.5445 
2 0.4288 0.4286 0.4388 0.4396 0.4405 0.4415 0.4426 0.4436 0.4446 0.4454 0.4460 0.4327 0.4329 0.4331 0.4331 
3 0.5399 0.5400 0.5336 0.5333 0.5331 0.5328 0.5323 0.5320 0.5317 0.5312 0.5308 0.5333 0.5338 0.5342 0.5343 
4 0.4667 0.4664 0.4756 0.4758 0.4759 0.4764 0.4770 0.4772 0.4774 0.4777 0.4776 0.4709 0.4713 0.4722 0.4731 
5 0.5110 0.5110 0.5147 0.5151 0.5152 0.5151 0.5152 0.5151 0.5147 0.5140 0.5133 0.5104 0.5108 0.5107 0.5106 
Predictive q
2




1 0.9934 0.9934 0.9940 0.9939 0.9938 0.9938 0.9938 0.9937 0.9936 0.9935 0.9935 0.9936 0.9935 0.9934 0.9934 
2 0.9941 0.9941 0.9940 0.9940 0.9939 0.9938 0.9938 0.9937 0.9937 0.9937 0.9937 0.9940 0.9939 0.9940 0.9938 
3 0.9930 0.9929 0.9938 0.9937 0.9937 0.9936 0.9935 0.9933 0.9932 0.9932 0.9932 0.9934 0.9934 0.9933 0.9933 
4 0.9944 0.9944 0.9945 0.9945 0.9944 0.9944 0.9943 0.9942 0.9941 0.9942 0.9941 0.9944 0.9943 0.9943 0.9942 
5 0.9938 0.9937 0.9939 0.9938 0.9938 0.9937 0.9938 0.9936 0.9934 0.9934 0.9933 0.9935 0.9934 0.9934 0.9934 
Average 0.9937 0.9937 0.9940 0.9940 0.9939 0.9938 0.9938 0.9937 0.9936 0.9936 0.9936 0.9938 0.9937 0.9937 0.9936 
 
  
Table 4.3 The 5-fold cross validation performance of the top-15 SVR QSAR models for predicting Cox2 inhibitors  
Model No. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 
Epsilon 0.19 0.20 0.21 0.22 0.23 0.24 0.25 0.26 0.27 0.34 0.35 0.36 0.37 0.38 0.39 






1 0.7731 0.7743 0.7753 0.7762 0.7771 0.7777 0.7782 0.7786 0.7790 0.7508 0.7511 0.7513 0.7515 0.7518 0.7521 
2 0.7657 0.7667 0.7678 0.7689 0.7699 0.7708 0.7717 0.7725 0.7732 0.7438 0.7443 0.7448 0.7450 0.7452 0.7455 
3 0.7794 0.7806 0.7816 0.7826 0.7836 0.7845 0.7852 0.7858 0.7864 0.7562 0.7566 0.7569 0.7571 0.7571 0.7571 
4 0.7832 0.7843 0.7852 0.7859 0.7866 0.7872 0.7877 0.7882 0.7887 0.7598 07602 0.7607 0.7611 0.7615 0.7619 






1 0.5113 0.5114 0.5115 0.5114 0.5115 0.5112 0.5108 0.5102 0.5097 0.5038 0.5040 0.5043 0.5044 0.5043 0.5041 
2 0.4899 0.4902 0.4904 0.4907 0.4909 0.4909 0.4909 0.4908 0.4905 0.4896 0.4892 0.4887 0.4883 0.4878 0.4876 
3 0.4651 0.4657 0.4662 0.4668 0.4675 0.4679 0.4685 0.4691 0.4693 0.4674 0.4671 0.4666 0.4657 0.4649 0.4639 
4 0.4525 0.4519 0.4515 0.4509 0.4503 0.4500 0.4499 0.4498 0.4497 0.4522 0.4526 0.4528 0.4530 0.4529 0.4531 
5 0.4673 0.4670 0.4663 0.4653 0.4648 0.4645 0.4640 0.4631 0.4625 0.4573 0.4580 0.4588 0.4593 0.4598 0.4601 
Predictive q
2




1 0.9682 0.9680 0.9679 0.9676 0.9676 0.9676 0.9677 0.9676 0.9672 0.9673 0.9669 0.9668 0.9665 0.9665 0.9663 
2 0.9671 0.9670 0.9669 0.9668 0.9666 0.9666 0.9663 0.9662 0.9659 0.9664 0.9663 0.9661 0.9661 0.9660 0.9658 
3 0.9677 0.9675 0.9675 0.9673 0.9670 0.9670 0.9669 0.9667 0.9666 0.9682 0.9680 0.9679 0.9677 0.9675 0.9674 
4 0.9678 0.9676 0.9676 0.9676 0.9673 0.9671 0.9671 0.9671 0.9669 0.9678 0.9677 0.9675 0.9673 0.9671 0.9669 
5 0.9675 0.9688 0.9675 0.9674 0.9676 0.9677 0.9675 0.9670 0.9668 0.9671 0.9672 0.9672 0.9669 0.9665 0.9663 
Average 0.9677 0.9676 0.9675 0.9673 0.9672 0.9672 0.9671 0.9669 0.9667 0.9673 0.9672 0.9671 0.9669 0.9667 0.9665 
  
Table 4.4 The performance of SVR and Chembench kNN QSAR in predicting the activity of DHFR, ACE and Cox2 inhibitors within and outside similarity-based 
applicability domain (AD) 
  DHFR inhibitors  ACE inhibitors  Cox2 inhibitors 
  SVR Chembench kNN  SVR Chembench kNN  SVR Chembench kNN 
R
2
 in 5-fold cross-validation tests  0.51-0.60 0.55-0.59  0.43-0.56 0.60-0.61  0.45-0.49 0.80-0.84 
R
2
 for post-2010 compounds within 
similarity-based AD 
 0.32 0.31  0.32 0.15  0.19 0.15 
R
2
 for post-2010 compounds outside 
similarity-based AD 
 NA NA  0.26 NA  0.15 NA 
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The ability of our models in predicting “new” inhibitors within the similarity-based ADs was 
tested by using the 26, 41 and 59 post-2010 DHFR, ACE and Cox2 inhibitors and 42, 20 and 43 
post-2010 non-inhibitors inside the similarity-based ADs defined by the method of the Tropsha 
group.
134, 137
 Figure 4.4-4.6 show the comparison of the actual and the predicted pIC50 values of 
our models and those of the Chembench generated consensus kNN QSAR models in identifying 
these “new” compounds. The R2 values of our models for predicting these “new” DHFR, ACE 
and Cox2 inhibitors and non-inhibitors are 0.32, 0.32 and 0.19 respectively, which are 
comparable to (or slightly better than) those of the consensus kNN QSAR models. These R
2
 
values are substantially lower than those evaluated by the 5-fold CV, but nonetheless close to the 
success criterion of 0.32.
289
 One possible reason for the lower R
2
 values is the higher level of 
structural novelty of the post-2010 vs the pre-2010 compounds than the training vs testing 
compounds in a 5-fold CV setting. Additionally, the relatively lower R
2
 for predicting “new” 
Cox2 inhibitors may further be attributed to the much higher diversity of the collected Cox2 
inhibitors included in the training set (spread in 901 families vs. 76 families for DHFR and 188 
families for ACE). 
The performance of our models in predicting highly novel inhibitors outside similarity-based ADs 
was assessed by using the 0, 6 and 13 post-2010 DHFR, ACE and Cox2 inhibitors and 4, 34 and 
7 post-2010 non-inhibitors outside the similarity-based ADs defined by the method of the 
Tropsha group.
134, 137
 The comparison of the actual and the predicted pIC50 values of our models 
in identifying these highly novel compounds is also shown in Figure 4.4-4.6. The R
2
 values of 
our models for predicting these highly novel DHFR, ACE and Cox2 inhibitors and non-inhibitors 
are 0.04, 0.26 and 0.15 respectively, which are slightly lower than those in predicting “new” 
inhibitors inside the similarity-based ADs. Therefore, our method has some level of capability in 
predicting the activity of highly novel actives outside similarity-based ADs. 
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Figure 4.4 The comparison of the actual and the predicted pIC50 values of SVR and ChemBench kNN 
QSAR models trained by pre-2010 inhibitors in predicting the activity of post-2010 DHFR inhibitors and 
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Figure 4.5 The comparison of the actual and the predicted pIC50 values of SVR and ChemBench kNN 
QSAR models trained by pre-2010 inhibitors in predicting the activity of post-2010 ACE inhibitors and 
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Figure 4.6 The comparison of the actual and the predicted pIC50 values of SVR and ChemBench kNN 
QSAR models trained by pre-2010 inhibitors in predicting the activity of post-2010 Cox2 inhibitors and 
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4.3.2 Virtual screening performance of SVR QSAR models in searching DHFR, 
ACE and Cox2 inhibitors from large libraries 
In evaluating the VS performance of our models in screening large chemical libraries, we used 
our models and the Chembench generated consensus kNN QSAR models to screen 168K MDDR 
compounds for identifying the 142, 357 and 939 known DHFR, ACE and Cox2 patented 
inhibitors that are inside the similarity-based ADs defined by the method of the Tropsha group
134, 
137
 (Table 4.5). A compound was identified as a virtual hit if the predicted pIC50>5. VS 
performance is typically measured by three quantities: yield (ratio of the identified and all known 
inhibitors in the searched libraries), hit rate (ratio of the identified inhibitors and all virtual hits) 
and enrichment factor (ratio of hit rate and random selection rate, which measures improvement 
over random selection). The yield, hit rate and enrichment factor of the DHFR, ACE and Cox2 
SVR QSAR models are 85.2%, 34.6% and 409.0 for DHFR, 86.3%, 30.5% and 143.4 for ACE, 
and 71.0%, 26.0% and 46.5 for Cox2 respectively, which are comparable to those of 81.0%, 21.1% 
and 249.2 for DHFR, 88.2%, 11.5% and 54.1 for ACE, and 66.9%, 9.2% and 16.5 for Cox2 by 
the Chembench kNN QSAR models. These results suggest that our method is capable of 
searching large chemical libraries at comparable yield and substantially improved hit rate and 
enrichment factor with respect to such established methods as the Chembench generated 
consensus kNN QSAR models.  
We further evaluated the capability of our models in searching highly novel actives from large 
chemical libraries by screening 168K MDDR compounds for identifying the 25, 175 and 51 
known DHFR, ACE and Cox2 patented inhibitors that are outside the similarity-based ADs 
defined by the method of the Tropsha group
134, 137
 (Table 4.5). The yield, hit rate, and enrichment 
factor of our models in identifying these highly novel DHFR, ACE and Cox2 from 168K MDDR 
compounds are 40.0%, 2.3% and 152.7 for DHFR, 45.7%, 1.7% and 16.1 for ACE, and 19.6%, 
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0.18% and 5.9 for Cox2 respectively, which suggests that our method has some level of capability 
in finding highly novel actives from large chemical libraries. Moreover, the VS performance our 
models in searching large chemical libraries were tested by screening 13.56 million PubChem 
compounds, which identified 26,217 (0.19%), 122,829 (0.91%) and 559,279 (4.12%) of the 
PubChem compounds as virtual DHFR, ACE and Cox2 inhibitor hits respectively. Even if all of 
these virtual hits turn out to be false, the maximum false hit rate would be no more than 0.19%, 
0.91% and 4.12% respectively. Therefore, our method is capable of searching large chemical 
libraries at very low false hit rate. We also analyzed the similarity levels of our identified 26,217, 
122,829 and 559,279 PubChem virtual DHFR, ACE and Cox2 inhibitor hits with respect to the 
pre-2010 DHFR, ACE and Cox2 inhibitors, which showed that these virtual hits are roughly 
equally distributed in different similarity ranges (Table 4.6-4.8 and Figure 4.7-4.9). This 
suggests that our QSAR models selected virtual hits not based on some form of similarity but 




Table 4.5 The performance of SVR and ChemBench kNN QSAR models trained by the same sets of pre-2010 inhibitors in searching 168K MDDR 
compounds for identifying the 167, 532 and 990 patented DHFR, ACE and Cox2 inhibitors within and outside similarity-based applicability domain (AD)  
   DHFR inhibitors  ACE inhibitors  Cox2 inhibitors 












No of compounds  3,685  3,706  15,842 
No of patented inhibitors  142  357  939 
No of virtual hits  350 546  1,011 2,739  2,566 6,800 
No of patented inhibitors identified  121 115  308 315  667 628 
Yield  85.2% 81.0%  86.3% 88.2%  71.0% 66.9% 
Hit rate  34.6% 21.1%  30.5% 11.5%  26.0% 9.2% 




No of compounds  164,295  164,283  152,109 
No of patented inhibitors  25  175  51 
No of virtual hits  440 NA  4,767 NA  5,561 NA 
No of patented inhibitors identified  10 NA  80 NA  10 NA 
Yield  40.0% NA  45.7% NA  19.6% NA 
Hit rate  2.3% NA  1.7% NA  0.18% NA 
Enrichment factor  152.7 NA  16.1 NA  5.9 NA 
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Table 4.6 The similarity levels of our identified PubChem virtual DHFR, inhibitor hits with respect to the 
pre-2010 DHFR inhibitors 
Tanimoto Total <10uM %<10uM <1uM %<1uM <100nM %<100nM 
0.0-0.1 168856 224 0.1327% 57 0.0338% 16 0.0095% 
0.1-0.2 541160 517 0.0955% 152 0.0281% 76 0.0140% 
0.2-0.3 1460146 1828 0.1252% 543 0.0372% 227 0.0155% 
0.3-0.4 1196544 2993 0.2501% 1173 0.0980% 295 0.0247% 
0.4-0.5 1688772 2292 0.1357% 479 0.0284% 106 0.0063% 
0.5-0.6 3420570 7940 0.2321% 2574 0.0753% 686 0.0201% 
0.6-0.7 3734182 7158 0.1917% 2188 0.0586% 799 0.0214% 
0.7-0.8 1157503 3192 0.2758% 1190 0.1028% 238 0.0206% 
0.8-0.9 180968 73 0.0403% 4 0.0022% 1 0.0006% 
0.9-1.0 12019 0 0.0000% 0 0.0000% 0 0.0000% 
Total 13560720 26217 0.1933% 8360 0.0616% 2444 0.0180% 
 
 
Table 4.7 The similarity levels of our identified PubChem virtual ACE, inhibitor hits with respect to the 
pre-2010 ACE inhibitors 
Tanimoto Total <10uM %<10uM <1uM %<1uM <100nM %<100nM 
0.0-0.1 122682 1259 1.0262% 228 0.1858% 25 0.0204% 
0.1-0.2 93791 517 0.5512% 72 0.0768% 17 0.0181% 
0.2-0.3 450593 5792 1.2854% 1453 0.3225% 431 0.0957% 
0.3-0.4 937720 7728 0.8241% 1947 0.2076% 777 0.0829% 
0.4-0.5 1516315 11707 0.7721% 2493 0.1644% 759 0.0501% 
0.5-0.6 2889486 25333 0.8767% 5394 0.1867% 1480 0.0512% 
0.6-0.7 5051559 46274 0.9160% 10646 0.2107% 3028 0.0599% 
0.7-0.8 2160888 21128 0.9777% 4722 0.2185% 1570 0.0727% 
0.8-0.9 324139 2980 0.9194% 305 0.0941% 61 0.0188% 
0.9-1.0 13547 111 0.8194% 15 0.1107% 3 0.0221% 
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Table 4.8 The similarity levels of our identified PubChem virtual Cox2, inhibitor hits with respect to the 
pre-2010 Cox2 inhibitors  
Tanimoto Total <10uM %<10uM <1uM %<1uM <100nM %<100nM 
0.0-0.1 111621 4716 4.2250% 909 0.8144% 140 0.1254% 
0.1-0.2 80528 3006 3.7329% 844 1.0481% 191 0.2372% 
0.2-0.3 332286 12928 3.8906% 2763 0.8315% 797 0.2399% 
0.3-0.4 793811 26527 3.3417% 4247 0.5350% 708 0.0892% 
0.4-0.5 958893 40430 4.2163% 8417 0.8778% 2133 0.2224% 
0.5-0.6 1090704 47289 4.3356% 9988 0.9157% 1840 0.1687% 
0.6-0.7 3659030 141041 3.8546% 26519 0.7248% 5541 0.1514% 
0.7-0.8 5067798 224226 4.4245% 47168 0.9307% 12078 0.2383% 
0.8-0.9 1385021 57036 4.1181% 10501 0.7582% 2352 0.1698% 
0.9-1.0 81028 2080 2.5670% 506 0.6245% 144 0.1777% 
Total 13560720 559279 4.1243% 111862 0.8249% 25924 0.1912% 
 
 
Figure 4.7 The similarity levels of our identified PubChem virtual DHFR inhibitor hits with respect to the 
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Figure 4.8 The similarity levels of our identified PubChem virtual ACE inhibitor hits with respect to the 
pre-2010 ACE inhibitors 
 
 
Figure 4.9 The similarity levels of our identified PubChem virtual Cox2 inhibitor hits with respect to the 
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CHAPTER 5 Virtual Screening of Selective Multi-target 
Kinase Inhibitors 
As illustrated in Chapter 3, one potential application of the Pathway Cross-talk Database (PCD) 
lies in facilitating system level studies of diseases and mechanism of drug combinations which 
was demonstrated by the analysis of the effect of glutamate on glioma cell invasion and the 
synergistic actions of tamoxifen-herceptin drug combination. Another potential usage of PCD is 
the systematic analysis of target combinations regulating multiple disease-related signaling 
pathways thus facilitating the discovery of multi-target agents.  
Multi-target agents have been increasingly explored for enhancing efficacy and reducing counter-
target activities and toxicities. Efficient virtual screening (VS) tools for searching selective multi-
target agents are desired. In Chapter 4, an epsilon-Support Vector Regression (ε-SVR) based 
high-throughput QSAR approach was developed and tested on DHFR, ACE and Cox2 inhibitors. 
In this chapter, this approach is applied as the VS tool for searching dual-inhibitors of 4 
combinations of 5 anticancer kinase targets, EGFR, VEGFR, PDGFR, Src and FGFR. 
5.1 Introduction 
Large percentage of drugs in development, which are typically directed at an individual target, 












 and on-target and off-target toxicities.
293
 Multi-target agents and 
drug-combinations have been increasingly explored
16, 17
 for enhancing therapeutic efficacies and 
improving safety and resistance profiles by selectively modulating the elements of these counter-
target and toxicity activities.
18
 In particular, multi-target kinase inhibitors are among the most 
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successful clinical anticancer drugs (e.g. sunitinib against PDGFR and VEGFR, dasatinib against 
Abl and Src, sorafenib against Braf and VEGFR, and lapatinib against EGFR and HER2) and 
have been actively pursued in current drug discovery efforts.
28, 294
 Methods for efficient search of 
multi-target agents are highly desired. 
Virtual screening (VS) methods have been widely explored for facilitating lead discovery against 
individual targets.
276, 295, 296









 and combination methods
300
 have been extensively used for VS of single-
target kinase inhibitors, but few multi-target VS studies have been reported.
301, 302
 An interesting 
strategy for identifying multi-target kinase inhibitors is to use  experimentally obtained small-
scale profiles for  predicting inhibitors of  a larger kinase set.
302
 In principle, single-target VS 
tools may be combined to collectively identify multi-target agents, which is practically useful if 
the individual VS tools have sufficiently high yields and low false-hit rates. High yields 
compensate for the reduced collective yields of combinatorial VS tools (For two statistically-
independent VS tools of 50%-70% yields, the collective yield of their combination is roughly the 
product of the yield of individual tools, which is 25%-49%). Low false-hit rates are needed for 
high enrichment factors in searching multi-target agents that are significantly fewer in numbers 
and more sparsely distributed in the chemical space than non-dual inhibitors (Table 5.1).  
A support vector regression (SVR) based high throughput QSAR method has been developed and 
may be potentially explored as multi-target VS tools because it has shown high yields and low 
false-hit rates in searching single-target agents for DHFR, ACE and Cox2 and is able to identify 
highly novel inhibitors even outside the similarity-based ADs. This method identifies active 
compounds in fast-speed by differentiating physicochemical profiles rather than structural 
similarity to active compounds per se, and requires no knowledge of target structure and no 
computation of structural flexibility, activity-related features, solvation effects and binding 
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affinities. The multi-target VS performance of this SVR QSAR method, which combine the 
prediction of two separate SVR QSAR models for each the multiple kinases, was tested by using 
it to search dual-inhibitors of combinations of 5 anticancer kinase targets EGFR, VEGFR, 
PDGFR, FGFR and Src. Figure 5.1 shows the illustration of using SVR QSAR methods for 
searching multi-target inhibitors. These kinase targets were selected because of their therapeutic 
relevance and the availability of sufficient number of the known inhibitors and dual-inhibitors.  
 
 
Figure 5.1 Illustration of using SVR QSAR method for searching multi-target inhibitors  
 
Based on dual-inhibitor availability, we focused on 4 kinase-pairs EGFR-VEGFR, EGFR-
PDGFR, EGFR-FGFR and EGFR-Src. As described in Section 3.3.3, these kinase-pairs are 
frequently co-expressed or co-activated in various cancers e.g. NSCLC,
303, 304
 and targeted by 
multi-target agents
28, 294
 with good anticancer efficacies. Inhibitors of growth factor receptor 
tyrosine kinases EGFR, VEGFR, PDGFR and FGFR have been successfully used for cancer 
treatments,
28, 305-309
 EGFR promotes proliferation and survival.
305
 VEGFR regulates angiogenesis 




. PDGFR modulates angiogenesis and growth, and is one of the multi-targets of 
several approved and clinical trial drugs.
28, 308
 FGFR regulates angiogenesis and cancer 
progression, and is one of the multi-targets of several clinical trial drugs.
28, 309
 Src modulates 
multiple pathways of cell growth, differentiation, migration and survival, and is part of the multi-
targets of several marketed and clinical trial drugs.
28, 310
  
Multi-target VS performance was tested by a rigorous method that assumes there is no explicit 
knowledge of known multi-target agents, because the number of known multi-target agents are 
generally small for many target-pairs. SVR QSAR models of each kinase were trained by using 
non-dual inhibitors of that kinase. The collective yield of SVR QSAR models of each kinase-pair 
(percent of known dual-inhibitors identified as dual-inhibitors) was estimated by using known 
dual-inhibitors of each kinase-pair. Target selectivity of each SVR QSAR model was assessed by 
using non-dual inhibitors of the kinase-pair and inhibitors of the other 3 kinases, out of the 5 
evaluated kinases, not included in the kinase-pair. Virtual-hit rates and false-hit rates in searching 
large compound libraries were evaluated by using 13.56 million PubChem, 168 thousand 
compounds from the MDL Drug Data Report (MDDR) database, and 1,175-9,356 MDDR 
compounds similar in structural and physicochemical properties to the known dual-kinase 
inhibitors. MDDR contains biologically relevant compounds (active against individual molecular 
target or biological assay) and well-defined derivatives reported in the patent literature, journals, 
meetings and congresses. PubChem and MDDR contain high percentages of inactive or active 
compounds significantly different from the dual-inhibitors, and the easily distinguishable features 
may make VS enrichments artificially good.
311
 Therefore, VS performance is more strictly tested 
by using subset of MDDR compounds similar to the dual-inhibitors so that enrichment is not 
simply a separation of trivial physicochemical features.
219
 
Chapter 5 Virtual Screening of Selective Multi-target Kinase Inhibitors 90 
 
5.2 Materials and methods 
5.2.1 Compound collection, training and testing datasets, molecular descriptors 
A total of 428-2,912 non-dual inhibitors of EGFR, VEGFR, PDGFR, FGFR and Src, and 67-256 
dual inhibitors of EGFR-VEGFR, EGFR-PDGFR, EGFR-FGFR and EGFR-Src, each with 
IC50≤10μM, were collected from ChEMBL database
158
. Dual-inhibitors and non-dual inhibitors of 
a kinase-pair refer to inhibitors of both and one of the two kinases respectively regardless of their 
activities against other kinases. Table 5.1 summarizes the statistics of these inhibitors and MDDR 
compounds similar to at least one of the dual-inhibitors. Figure 5.2 shows the Venn graph of our 
collected dual-inhibitors the 4 evaluated kinase pairs and non-dual-inhibitors of the 5 evaluated 
kinases. As few non-inhibitors have been reported, putative non-inhibitors of each kinase were 
generated by following the same protocol as described previously in Section 2.2.1.3 and Section 
4.2.1. As a result, a total of 7,628-8,241 compounds extracted from the 7,628-8,241 families (1 






Table 5.1 Datasets of dual-inhibitors and non-dual-inhibitors of the kinase-pairs used for developing and testing combinatorial SVM dual-inhibitor virtual 
screening tools. Additional sets of 13.56 million PubChem compounds and 168 thousand MDDR active compounds were also used for the test.  




for Kinase A 
No of inhibitors of A that are non-inhibitor of 
B (No of families) 
2,142 (635) 2,343 (666) 2,308 (658) 2,150 (631) 
No of  these inhibitors that are in the B 
inhibitor families (No of families) 
1,309 (255) 457 (95) 455 (87) 672 (165) 
No of these inhibitors that are in the families of 
dual inhibitors (No of families) 
600 (79) 217 (26) 244 (38) 368 (74) 
Training set 
for Kinase B 
No of inhibitors of B that are non-inhibitor of 
A (No of families) 
2,912 (795) 675 (212) 428 (182) 1,444 (437) 
No of these inhibitors that are in the A 
inhibitors families (No of families) 
1,293 (255) 347 (95) 256 (87) 768 (165) 
No of  these inhibitors that are in the families 
of dual inhibitors of A and B (No of families) 






of A and B 
No of dual inhibitors of A and B (No of 
families) 
256 (121) 67 (40) 91 (58) 256 (123) 
No (%) of dual inhibitors in the families that 
contain both A and B non-dual inhibitor in 
training sets 
171 (66.8%) 28 (41.8%) 42 (46.2%) 122 (47.7%) 
No (%) of dual inhibitors of A and B as 
inhibitor of at least one of the other 3 kinases 
studied in this work 
171 (66.8%) 45 (67.2%) 67 (73.6%) 146 (57.0%) 
No (%) of dual-inhibitors of A and B as 
inhibitor of more than 1 of the other 3 kinases 
studied in this work 
21 (8.2%) 23 (34.3%) 23 (25.3%) 18 (7.0%) 
Inhibitors of 
other 3 kinases 
No of inhibitors 1,816 4,051 4,298 3,282 
MDDR 
Compounds 
Similar to Dual 
Inhibitors of A 
and B 
No of compounds 9,356 1,175 1,285 5,404 
 




Figure 5.2 The Venn graph of the collected dual-inhibitors the 4 evaluated kinase-pairs and non-dual-
inhibitors of the 5 evaluated kinases 
 
The collected non-dual and dual inhibitors of EGFR, VEGFR, PDGFR, FGFR and Src, are 
distributed in 682, 833, 236, 205 and 488 families respectively, which is consistent with reported 
191 unique scaffolds (154 clusters and 43 singletons) for 565 kinase inhibitors
299
.  Because of the 
extensive efforts in searching kinase inhibitors, the number of undiscovered “inhibitor” families 
for each kinase in PubChem and MDDR is expected to be relatively small, most likely no more 
than several hundred families. The ratio of the “inhibitor” and “inactive” families for each kinase 
(hundreds families vs 7,628-8,241 families contained in PubChem and MDDR at present) is 
expected to be no more than ~999/8500, which is <13%. Therefore, putative non-inhibitor 
training dataset can be generated by extracting a few representative compounds from each of the 
families that contain no known inhibitor, with a maximum possible “wrong” prediction rate of 
<13% even in the extreme and unlikely cases that all of the undiscovered inhibitors are misplaced 
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into the non-inhibitor class. The noise level generated by up to 13% “wrong” negative family 
representation is expected to be substantially smaller than the maximum 50% false-negative noise 
level tolerated by SVR QSAR models
312
. It is noted that 18.2%-25.0% of the dual-inhibitor 
families contain no non-dual inhibitor of the same kinase-pair, whose representative compounds 
were included in the inactive training datasets as dual-inhibitors are supposed to be unknown in 
our study. A substantial percentage of the dual-inhibitors in these “non-inhibitor” families were 
nonetheless identified as dual-inhibitors by our SVR QSAR models.  
In this work, a total of 98 2D physicochemical descriptors generated from the MODEL
194
 
program were used. The detailed description of these molecular descriptors can be found in 
Section 2.2.2. 
5.2.2 Computational models 
A MLR method, support vector regression (SVR), is used for deriving QSAR models because it 
has consistently performed well,
135, 280-285
 is less penalized by sample redundancy and has lower 
over-fitting risks.
286, 287
 The objective of SVR is to find a function that minimally deviates from 
the activity values of the training compounds within a tube of radius ε.211 For modeling 
chemically-diverse compounds, SVR typically maps the compounds into a higher dimensional 
space by using a kernel function. The detailed mathematical algorithms of SVR were described in 
Section 2.2.3. In this work, our SVR models were developed by using LIBSVM
288
 with RBF 
kernel,
214-216
 a hard margin C=1,000.  
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5.3 Results and discussion 
5.3.1 Dual-inhibitors and non-dual inhibitors of the studied kinase-pairs 
As shown in Table 5.1, the numbers of dual-inhibitors and non-dual inhibitors of the kinase-pairs 
are 256, 2,142 and 2,912 for EGFR-VEGFR, 67, 2,343 and 675 for EGFR-PDGFR, 91, 2,308 and 
428 for EGFR-FGFR, and 256, 2,150 and 1,444 for EGFR-Src respectively. The dual-inhibitors 
and non-dual inhibitors are distributed in 40-123 and 182-795 families respectively. Hence, both 
the numbers and diversity of non-dual inhibitors and dual-inhibitors are at reasonable levels for 
developing and testing VS tools. The percentages of dual-inhibitors outside the common families 
of the non-dual inhibitors in the training datasets are 33.2% for EGFR-VEGFR, 58.2% for EGFR-
PDGFR, 53.8% for EGFR-FGFR, and 52.3% for EGFR-Src respectively. Therefore, these dual-
inhibitors have substantial degree of novelty against non-dual inhibitors. Moreover, 57.0%-73.6% 
of the dual-inhibitors of the kinase pairs are inhibitor of at least one of the other 3 kinases, but 
only up to 34.3% of the dual-inhibitors are inhibitor of at least 2 of the other 3 kinases. Hence, 
most of these dual-inhibitors are non-ubiquitous inhibitors and show some degree of kinase 
selectivity even though the majority of them target more than 2 kinases.  
5.3.2 Virtual screening performance of SVR QSAR models in searching kinase dual-
inhibitors from large libraries 
The VS performance of SVR QSAR models in identifying dual-inhibitors of the 4 kinase-pairs is 
summarized in Table 5.2 and further shown in Figure 5.3. The parameters of the developed SVR 
regression models for the evaluated kinases are in the ranges of =0.39-0.90 and σ=0.18-0.23. 
The dual-inhibitor yields are 42.2% for EGFR-VEGFR, 32.8% for EGFR-PDGFR, 22.0% for 
EGFR-FGFR, and 30.1% for EGFR-Src respectively. The yields for the intra- kinase pairs are 
comparable to the expected 25%-49% yields of combinations of good VS tools with individual 
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yields of 50%-70%. Therefore, our SVR QSAR methods show reasonably good capability in 
identifying multi-target agents for kinase-pairs within a protein kinase group without requiring 
explicit knowledge of multi-target agents.  
 
Figure 5.3 The VS performance of SVR QSAR models in identifying dual-inhibitors of 4 combinations of 














EGFR-VEGFR EGFR-PDGFR EGFR-FGFR EGFR-Src
Yield
False hit rate for inhibitors of kinase A
False hit rate for inhibitors of kinase B
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Table 5.2 Virtual screening performance of SVR QSAR models for identifying dual-inhibitors of 4 
combinations of EGFR, VEGFR, PDGFR, FGFR and Src 







Yield (No of virtual 
hits) 
42.2% (108) 32.8% (22) 22.0% (20) 30.1% (77) 
No (%) of identified 
true hits outside the 
common training 
active families of 
both kinases 
27 (25.0%) 9 (40.9%) 9 (45.0%) 33 (42.9%) 
Non-dual 
inhibitors of the 
same kinase pair 
False hit rate for 
inhibitors of kinase A 
60.2% 26.1% 13.6% 50.1% 
False hit rate for 
inhibitors of kinase B 
25.7% 32.7% 18.2% 43.3% 
Inhibitors of 
other 3 kinases 
False hit rate 33.9% 18.3% 7.1% 12.5% 
MDDR 
compounds 
similar to dual 
inhibitors 










All 168 thousand 
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Target selectivity was tested by using SVR QSAR models to screen the 428-2,912 non-dual 
inhibitors of the 4 kinase-pairs, which misidentified 60.2% and 25.7% of the non-dual inhibitors 
of the kinase pair as dual-inhibitors for EGFR-VEGFR, 26.1% and 32.7% for EGFR-PDGFR, 
13.6% and 18.2% for EGFR-FGFR, and 50.1% and 43.3% for EGFR-Src respectively. Therefore, 
these SVR QSAR models showed some selectivity in distinguishing dual-inhibitors from non-
dual inhibitors yet with unsatisfactory false hit rate in some cases, e.g. 60.2% of the EGFR non-
dual inhibitors were identified as EGFR-VEGFR dual inhibitors, and 50.1% of the EGFR non-
dual inhibitors were identified as EGFR-Src dual inhibitors. There are two possible reasons for 
Chapter 5 Virtual Screening of Selective Multi-target Inhibitors 97 
 
the misidentification of a substantial percentage of non-dual inhibitors as dual-inhibitors. First, 
SVR QSAR models were trained by non-dual inhibitors only, which may not fully distinguish 
dual and non-dual inhibitors. Secondly, some of the misidentified non-dual inhibitors are 
probably true dual-inhibitors not yet experimentally tested for multi-target activities. It is noted 
that “mistaken” selection of these non-dual inhibitors is still useful for searching single-target 
leads. 
Target selectivity was further tested by using SVR QSAR models to screen the 1,816-4,298 
inhibitors of the other 3 kinases not included in a particular kinase-pair. We found that 33.9% of 
these inhibitors were misidentified as dual-inhibitors for EGFR-VEGFR, 18.3% for EGFR-
PDGFR, 7.1% for EGFR-FGFR and 12.5% for EGFR-Src respectively. These showed that our 
SVR QSAR models are fairly selective in separating inhibitors of specific kinase pair from those 
of other kinases.  
Virtual-hit rates and false-hit rates of our SVR QSAR method in screening compounds that 
resemble the structural and physicochemical properties of the training datasets were evaluated by 
using 1,175-9,356 MDDR compounds similar to a dual-inhibitor of each kinase pair. Similarity 
was defined by Tanimoto similarity coefficient ≥0.9 between a MDDR compound and its closest 
dual-inhibitor.
33
 Our SVR QSAR models identified 691 virtual-hits from 9,356 MDDR similarity 
compounds (virtual-hit rate 7.39%) for EGFR-VEGFR, 194 from 1,175 MDDR compounds 
(16.51%) for EGFR-PDGFR, 85 from 1,285 MDDR compounds (6.61%) for EGFR-FGFR, and 
319 from 5,404 MDDR compounds (5.90%) for EGFR-Src respectively.  
Significantly lower virtual-hit rates and thus false-hit rates were found in screening large libraries 
of 168 thousand MDDR and 13.56 million PubChem compounds.  The numbers of virtual hits 
and virtual-hit rates in screening 168 thousand MDDR compounds are 2,605 and 1.55% for 
EGFR-VEGFR, 1,557 and 0.93% for EGFR-PDGFR, 654 and 0.39% for EGFR-FGFR, and 1,656 
Chapter 5 Virtual Screening of Selective Multi-target Inhibitors 98 
 
and 0.99% for EGFR-Src respectively. The numbers of virtual hits and virtual-hit rates in 
screening 13.56M PubChem compounds are 102,497 and 0.74% for EGFR-VEGFR, 61,764 and 
0.46% for EGFR-PDGFR, 18,981 and 0.14% for EGFR-FGFR, and 52,498 and 0.39% for EGFR-
Src respectively.  
Substantial percentages of the MDDR virtual-hits belong to the classes of antineoplastic, 
tyrosine-specific protein kinase inhibitors, and signal transduction inhibitors (Table 5.3). As 
some of these virtual-hits may be true dual-inhibitors, the false-hit rates of our SVR QSAR 
models are at most equal to and likely less than the virtual-hit rates. Hence the false-hit rates are 
satisfactorily low with ≤6.61%-16.51% in screening 1,175-9,356 MDDR similarity compounds, 
≤0.39%-1.55% in screening 168 thousand MDDR compounds, and ≤0.14%-0.74% in screening 
13.56 million PubChem compounds, which are comparable and in some cases better than single-
target false-hit rates of 0.0054%-8.3% of single-target support vector machine (SVM) methods,
276, 
296
 0.08%-3% of structure-based methods, 0.1%-5% by other machine learning methods, 0.16%-
8.2% by clustering methods, and 1.15%-26% by pharmacophore models.
313
 
5.3.3 Evaluation of SVR QSAR models identified MDDR virtual hits 
Our SVR QSAR models identified MDDR virtual-hits were evaluated based on the known 
biological or therapeutic target classes specified in MDDR. Table 5.3 gives the MDDR classes 
that contain higher percentage (≥5%) of SVR QSAR virtual hits and the percentage values. We 
found that 248-1,092 or 36.4%-41.9% of the 654-2,605 virtual hits belong to the antineoplastic 
class, which represent 1.3%-5.6% of the 19,643 MDDR compounds in the class. In particular, 67-
341 or 10.2%-14.8% of the virtual hits belong to the tyrosine-specific protein kinase inhibitor 
class, which represent 5.7%-28.9% of the 1,181 MDDR compounds in the class. Moreover, 76-
268 or 9.9%-13.8% of the virtual hits belong to the signal transduction inhibitor class, 
representing 3.7%-13.2% of the 2,037 members in this class. Therefore, many of the SVR QSAR 
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virtual hits are antineoplastic compounds that inhibit tyrosine kinases and possibly other kinases 
involved in signal transduction, angiogenesis and other cancer-related pathways. While some of 
these kinase inhibitors might be true dual-inhibitors of specific kinase-pairs, the majority of them 
are expected to arise from false selection of non-dual inhibitors of the same kinase-pairs (at 
13.6%-60.2% false-hit rates) and inhibitors of other kinases (at 7.1%-33.9% false-hit rates).  
Some of the SVR QSAR virtual hits belong to the antiarthritic class. All of our evaluated kinases 
or their kinase-likes have been linked to arthritis in the literature. EGFR-like receptor stimulates 
synovial cells and its elevated activities may be involved in the pathogenesis of rheumatoid 
arthritis.
296
 VEGF has been related to such autoimmune diseases as systemic lupus erythematosus, 
rheumatoid arthritis, and multiple sclerosis.
314
 FGFR may partly mediate osteoarthritis.
315
 PDGF-
like factors stimulates the proliferative and invasive phenotype of rheumatoid arthritis synovial 
connective tissue cells.
316
 Therefore, some of the SVR QSAR virtual hits in the antiarthritic class 
may be inhibitors of our evaluated kinases or their kinase-likes capable of producing antiarthritic 
activities.  
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Table 5.3  MDDR classes that contain higher percentage (≥5%) of virtual-hits identified by combinatorial 
SVMs in screening 168 thousand MDDR compounds for dual-inhibitors of 4 combinations of EGFR, 
VEGFR, PDGFR, FGFR and Src. 
 
Kinase Pair 
No of SVR 
Identified 
Virtual Hits 
MDDR Classes that Contain Higher 












Antineoplastic 1,092 41.9% 
Tyrosine-Specific Protein Kinase Inhibitor 341 13.1% 
Antiarthritic 298 11.4% 
Signal Transduction Inhibitor 268 10.3% 




Antineoplastic 566 36.4% 
Tyrosine-Specific Protein Kinase Inhibitor 209 13.4% 
Antiarthritic 180 11.6% 
Signal Transduction Inhibitor 154 9.9% 




Antineoplastic 248 37.9% 
Antiarthritic 76 11.6% 
Signal Transduction Inhibitor 76 11.6% 
Tyrosine-Specific Protein Kinase Inhibitor 67 10.2% 
Antihypertensive 42 6.4% 
EGFR-Src 1,656 
Antineoplastic 677 40.9% 
Tyrosine-Specific Protein Kinase Inhibitor 245 14.8% 
Signal Transduction Inhibitor 228 13.8% 
Antiarthritic 174 10.5% 
Cephalosporin 112 6.8% 
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5.4 Further perspective 
The high throughput SVR QSAR VS tools developed by using non-dual inhibitors show good 
capability in identifying dual-inhibitors of several anticancer target kinase-pairs at comparable 
and in many cases substantially lower false-hit rates than those of typical VS tools reported in the 
literature. The capability of the SVR QSAR models and other VS tools in identifying multi-
kinase inhibitors and other multi-target agents may be further enhanced by incorporating 
knowledge of multi-target agents into VS tool development processes. With the discovery of 
increasing number of selective multi-target agents from the current and future drug discovery 
efforts, it is possible to introduce more comprehensive elements of distinguished structural and 
physicochemical features of selective multi-target agents into the training of combinatorial VS 
tools for more effective identification of selective multi-target agents. These multi-target VS tools 
may be combined with structure-based filters for enhanced target selectivity. Because of the high 
computing speed and generalization capability, our SVR QSAR method can be potentially 
explored to develop useful VS tools to complement other VS methods or to be used as part of 




Chapter 6 Concluding Remarks                                               102 
 
CHAPTER 6 Concluding Remarks 
This last chapter summarizes the major findings and contributions of this study (Section 6.1). 
Limitations of present study and suggestions on possible areas for further studies are discussed in 
Section 6.2. 
6.1 Major findings and contributions 
In this work, a Pathway Cross-talk Database (PCD) was developed providing information on 
experimentally confirmed pathway cross-talks with detailed information about the interactive 
mediators and mechanisms. PCD currently contains 137 entries of experimentally discovered 
pathway cross-talks described in the literature. There are a total of 89 pathways or pathway 
components covering 78 diseases or biological processes included in the database. Rapid 
advances in the study of systems level regulations and cross-talks and in the investigation of their 
molecular mechanisms are expected to generate more information and stimulate more interest in 
exploring pathway cross-talks for regulating biological processes via chemical and other means, 
and for discovering multi-targeting drugs and drug combinations. By incorporating the relevant 
information generated from these studies, PCD may complement and expand the application 
scope of other pathway databases to facilitate systems-level studies of biological regulations and 
disease processes, and the discovery of multi-targeting drugs and drug combinations. At last, four 
combinations of five kinases, EGFR-VEGFR, EGFR-PDGFR, EGFR-FGFR and EGFR-Src, have 
been identified as promising targets for treating NSCLC.  
Machine learning (ML) methods have been explored for developing QSAR models as alternative 
VS tools searching single- and multi-target agents because of their high-CPU speed and 
capability for covering highly diverse spectrum of compounds. However, while exhibiting 
Chapter 6 Concluding Remarks                                               103 
 
equally good hit selection and activity assessment performance in screening large libraries, the 
currently developed ML QSAR VS tools cannot identify highly novel inhibitors outside 
similarity-based ADs. In this work, a high throughput QSAR approach was developed using 
support vector regression (SVR) as the regression algorithm and tested whether the performance 
of SVR QSAR models can be improved by using training sets of diverse inactive compounds. 
Apart from the use of known inactive compounds and active compounds of other biological target 
classes as putative inactive compounds, an in-house algorithm was applied for generating putative 
inactive compounds. An advantage of this approach is its independence on the knowledge of 
known inactive compounds and active compounds of other biological target classes, which 
enables more expanded coverage of the “inactive” chemical space in cases of limited knowledge 
of inactive compounds and compounds of other biological classes. Our models performed well in 
predicting new inhibitors reported after the year of 2010 with R
2
 values comparable to those of 
other QSAR models. In retrospective database screening of active compounds from large libraries 
such as PubChem and MDDR, our SVR QSAR models also showed improved hit-rates and the 
enrichment factors. Moreover, our method showed some level of capability in the identification 
and activity assessment of highly novel inhibitors outside similarity-based ADs (as summarized 
in Table 6.1). The putative negatives generation method plays an important role in it. This 
method greatly increased the performance of VS without compromising performance within ADs. 
It showed that at the study of chemistry and biological problems, certain assumption could be 
made to solve the problems although sometimes it may lead to certain degree of noise. 
Our SVR QSAR models were tested as VS tools for searching dual-inhibitors of 4 combinations 
of 5 anticancer kinase targets (EGFR, VEGFR, PDGFR, FGFR and Src). SVR QSAR Models 
were fairly selective in misidentifying as dual-inhibitors of the non-dual inhibitors of the same 
kinase-pairs and produced low false-hit rates in misidentifying as dual-inhibitors of PubChem and 
MDDR databases. Compared with other methods, our SVR QSAR models show good capability 
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in identifying dual-inhibitors of several anticancer target kinase-pairs at comparable and in many 
cases substantially lower false-hit rates. Therefore, SVR QSAR models are potentially useful to 
discover multi-target agents for enhancing efficacy and reducing counter-target activities and 
toxicities. 
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similar to each other 




linear ML (e.g. 
kNN, ANN, 
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6.2 Limitations and suggestions for future studies  
The Pathway Cross-talk Database (PCD) is potentially useful for facilitating the systems level 
understanding of diseases, biological processes and treatment strategies. However, recently we 
realized that the old literature searching strategy was flawed during the database information 
collection step. In the year 2007 to 2008 when we first tried to develop this database, we used the 
keyword “crosstalk” combined with either “pathway” or “network” or “protein” to identify the 
literature that describe experimentally discovered cross-talk between two different pathways. 
However, the word “crosstalk” is only one way but not the most common. A PubMed search of 
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“cross-talk” combined with “pathway”, for instance, results in over twice as many entries as 
“crosstalk” combined with “pathway”. This is one example that the old strategy was inadequate 
which resulted in a lot of relevant literature or data that should be collected in the database missed 
out and made this database an under-representation of the experimentally confirmed pathway 
cross-talks. Therefore, the current version of the database and the old strategy we used can only 
be seen as a prototype of a potential route towards a future comprehensive pathway cross-talk 
database. The searching strategy needs to be improved, for example, by adopting more proper 
keyword terms, aside from the old ones, such as "cross-talk" or "interaction" or "linkage" 
combined with "pathway" or "network". 
On the other hand, it has been years since PCD was developed. It is now out of date because 
many useful papers have been published since then. For example, over 800 new papers were 
published since 2009 by searching PubMed using the term "crosstalk AND pathway". Thus new 
entries from the new papers in recent years will also be added to make this database up to date. 
The SVR QSAR models developed using our putative negative dataset are not perfect. There are 
still some false hits that cannot be ruled out easily. These false hits are “correctly” identified by 
our SVR QSAR models due to the similar structural frameworks with real active compounds. Our 
molecular descriptors used in the SVR QSAR models are insufficient to adequately differentiate 
the compounds with similar structural frameworks. Therefore, it is necessary to explore different 
combinations of descriptors and to select any more optimal sets of descriptors by using more 
refined feature selection algorithms and parameters in future work. It may also be helpful to 
introduce new descriptors for more appropriate representation of compounds or descriptors which 
can be used to describe the interaction between targets and the ligands. 
The putative negatives generation method helps a lot in improving the performance of SVR 
QSAR models in VS large chemical libraries. However, a drawback of this approach lies in the 
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possible inclusion of some undiscovered active compounds in the “inactive” class, which may 
affect the capability of ML methods for identifying novel active compounds. As will be 
demonstrated, such an adverse effect is expected to be relatively small for many biological target 
classes. On the other hand, the clustering of chemical space can also affect the generation of 
putative negative dataset. Chemical space clustering is a difficult area in cheminformatics that is 
clustering method, distance metrix selection and molecular descriptors dependent. K-means 
clustering method used in this work is not the best clustering method but is suitable and 
computable for large chemical spaces. In future studies, new clustering algorithm can be 
developed for improving the accuracy of chemical space clustering. The selection of correlation 
coefficients and other chemical descriptors such as fingerprint also can be the direction of 
improvement.   
Our SVR QSAR models showed the good performance in VS large chemical libraries with 
improved hit rate, yield and enrichment factor. Furthermore, our SVR QSAR models also showed 
some capability in identifying highly novel actives beyond similarity-based ADs. At this point, 
experimental studies are necessary for validating our high performance virtual screening tools. 
Based on this, we have formed extensive collaborations with several research groups and some 
compounds have been selected and sent to our collaborators for further study.  
The capability of the SVR QSAR models in identifying multi-kinase inhibitors and other multi-
target agents needs to be further enhanced by incorporating knowledge of multi-target agents into 
VS tool development processes. With the discovery of increasing number of selective multi-target 
agents from the current and future drug discovery efforts, it is possible to introduce more 
comprehensive elements of distinguished structural and physicochemical features of selective 
multi-target agents into the training of combinatorial VS tools for more effective identification of 
selective multi-target agents. 
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These years have seen plenty of debate aimed to define which of the many VS approaches the 
best is. However, this question remains not answered conclusively. Each approach has its own 
advantages and drawbacks, and the choice of one or the other depends on the particular research 
question faced by the medicinal chemist. In terms of performance, ligand based methods tend to 
present better enrichment factors and higher speed serving as a more efficient methodologies to 
remove non active compounds while target based method provides a more straightforward picture 
of interactions between the drug and molecular target and a better prediction in terms of novel 
structures. Now synergistic, rational and synthetic combinations of different approaches make a 
possible trend for future drug discovery. Combined VS approach tends to include less costly 
approaches, usually ligand based VS, at the first stage, while the most demanding methods, 
usually docking, for the last stage when the original large compound library has been reduced to a 
manageable size. 
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